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SUMMARY 
 
Genetic studies using families have successfully identified many disease genes 
causing Mendelian diseases. Familial myeloproliferative disorders (MPD) offer 
interesting opportunities to identify disease genes involved in the thrombopoiesis 
and erythropoiesis, and some undiscovered genetic components might also 
contribute to the etiology of the sporadic MPD. 
 
Hereditary thrombocythemia (HT) is an autosomal dominant disorder with clinical 
features resembling sporadic essential thrombocythemia. HT families share 
similar clinical symptoms caused by heterogeneous genetic alterations. Inherited 
germ-line mutations in the thrombopoietin (TPO) gene and its receptor MPL have 
been found causing thrombocytosis in a number of HT families. Five reported 
mutations in the thrombopoietin gene are all located in the 5 prime untranslated 
region (5’UTR) and cause overproduction of Tpo protein by the same 
mechanism: increased translation efficiency for the mutant mRNAs. One 
mutation identified in the MPL gene is located at the transmembrane domain and 
results in a hyperactive receptor, thereby leading to thrombocytosis. All these 
germ-line mutations have not been found in sporadic patients and are only 
responsible for the etiology of some HT families, indicating that the occurrence of 
these germ-line mutations is a rare event. The disease-causing genes for many 
HT families remain unknown. Identifying genetic lesions in these families will 
increase our knowledge of the physiology of thrombopoiesis and some of these 
unknown genetic components may contribute to the pathogenesis in sporadic 
MPD patients.  
 
In the first part of the project for genetic studies of HT families, the TPO and MPL 
genes were analyzed by genomic DNA exon sequencing and linkage analysis. A 
splice donor mutation in the TPO gene was identified in a Polish family. This 
mutation was previously identified in a Dutch family and the reoccurrence of this 
rare mutation has not been reported to date. In order to determine whether the 
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mutation in these two families arose de novo or from a founder effect, haplotype 
analysis was performed to examine polymorphic DNA sequences in the vicinity of 
the mutation using microsatellites and single nucleotide polymorphism (SNP) in 
these two families. Six microsatellite markers on the affected allele showed 
different sizes in PCR products and 3 SNPs close to the mutation differed in their 
sequences between the two families. We therefore concluded that the mutation 
in these two families occurred de novo. The previously reported MPL mutation at 
the transmembrane domain of MPL protein was identified in one of the HT 
families studied here. Recently, 5 additional HT families were found carrying this 
mutation. We conducted haplotype analysis using microsatellite markers in the 
MPL gene locus for the 6 HT families. Four microsatellite markers surrounding 
the MPL mutation showed identical sizes in the PCR products on the affected 
allele, suggesting that the MPL mutation occurred from a single founder event. 
This may explain the high frequency of this mutation in HT families.  
 
In a large US family with HT, where the TPO and MPL genes were excluded as 
disease causes, genome-wide linkage analysis was performed aiming to identify 
novel genetic component for the thrombocytosis phenotype. Two genetic regions 
with significant logarithm of odds (LOD) score values have been located using 
microsatellites and SNP chip arrays. Candidate gene sequencing revealed one 
novel polymorphism in the gelsolin gene, which encodes an actin-binding protein 
abundant in platelets. Gelsolin has multiple biological functions in addition to 
cytoskeletal actin modulation. Functional studies in cell proliferation assays and 
mouse bone marrow transplantation did not validate this polymorphism as an 
active disease causing mutation. Further studies on this polymorphism in platelet 
biogenesis are planned for the future. In addition, sequencing of all the candidate 
genes in the segregating regions is in progress.  
 
In a second project, genome-wide linkage analyses were performed using 
microsatellites and SNP chip arrays in a family with secondary polycythemia 
inherited in an autosomal recessive mode. Both parametric and nonparametric 
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linkage analysis were conducted for this family. Five genetic regions were found 
linked to the disease phenotype. A few candidate genes were sequenced and 
studied, however no genetic variation was found so far. Additionally, no 
mutations were found in several genes involved in erythropoiesis and oxygen 
sensing pathway. Burst forming units-Erythroid cultures in hypoxia condition 
showed high expression of the EPO gene in 3 out of 4 affected family members, 
suggesting a potential unknown defect in the oxygen-sensing pathway. 
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GENERAL INTRODUCTION 
 
Hematopoiesis 
Hematopoiesis is the process of blood cell formation that lasts the entire lifetime. 
In humans, hematopoiesis occurs initially in the yolk sac of an embryo at the first 
few weeks and then moves to fetal liver and spleen until 6 to 7 months, when 
bone marrow develops into the main site of blood production and remains the 
major source of new blood cells throughout normal life.   
One type of self-renewable and pluripotent hematopoietic stem cell (HSC) gives 
rise to all cell types in blood.1 Initial differentiation of HSC is along two major 
pathways: myeloid or lymphoid. Common myeloid precursors develop into 
multiple cell types including erythrocytes, megakaryocytes (sources of platelets), 
granulocytes, and macrophages.2 Common lymphoid progenitors give rise to B 
and T lymphocytes and natural killer cells.3 Each cell type has specific functions 
and a distinct development procedure, which is regulated tightly through 
interactions between progenitor cells and various growth factors.  
 
Megakaryopoiesis and Thrombopoiesis  
Megakaryocytes are giant cells in bone marrow with a single, mutilobulated, 
polyploidy nucleus. Like other hematopoietic cell types, mature megakaryocytes 
are derived from pluripotent HSCs through a process called megakaryopoiesis. 
The major function of the megakaryocytes is to generate platelets in peripheral 
blood (thrombopoiesis). Platelets are anucleate cells formed by fragmentation of 
megakaryocyte cytoplasma and play important roles in hemostasis and 
thrombosis of peripheral blood vasculature. The regulation of megakaryopoiesis 
involves numerous cytokines, transcription factors and their target genes.  
 
Thrombopoietin and thrombopoietin receptor c-MPL 
The key regulatory cytokine in megakayopoiesis is thrombopoietin (TPO), which 
binds to its receptor c-MPL on megakaryocyte surfaces and supports the entire 
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process of megakaryocyte development, maturation and platelet production.4 
Knocking out of either the TPO gene or the c-MPL gene leads to 85% reduction 
of platelet counts in mice,5,6 highlighting the central role of this ligand-receptor 
reaction in megakaryopoiesis.  
Although being sought for long, the TPO gene was not identified molecularly until 
its receptor c-MPL gene was discovered from a study on the murine 
myeloproliferative leukemia virus (MPLV).7 A novel virus oncogene v-MPL 
encoding part of an unknown member of the cytokine receptor superfamily was 
identified8 and homolog searching in human and mouse led to cloning of the 
corresponding cellular protooncogene c-MPL.9-11 Using c-Mpl as an essential 
tool, the gene encoding its ligand Tpo was soon cloned by several groups 
simultaneously.12-15 
Human TPO gene is located on chromosome 3q2716 with 5 coding exons and 2 
upstream noncoding exons,17-19 which result in a long 5 prime untranslated 
region (5’UTR) of TPO mRNA with additional 7 upstream initiation codons. These 
upstream start codons can bind to 40S ribosomal subunits and initiate premature 
translation of upstream open reading frames (uORF), which encode short and 
functionless polypeptides. These translations thereby suppress the binding of 
ribosome to the physiological start codon.20,21 Five different mutations in the 
5’UTR of the TPO gene have been described in families with hereditary 
thrombocythemia that cause increased efficiency of mRNA translation of TPO 
protein.22-27 These types of uORF only exist in 10% of mRNA transcripts in 
human, but are often found in highly regulated genes.28 The TPO cDNA predicts 
a polypeptide of 353 amino acids including a 21 amino acid secretary leader 
sequence.29 The TPO protein consists of 2 domains: the N-terminal and the C-
terminal domains. The N-terminal portion of 154 amino acids has striking 
homology with erythropoietin (EPO) and represents the receptor-binding domain 
of hormone. This domain, like EPO and other members of the hematopoietic 
growth factor family, is expected to fold into an anti-parallel four-helix bundle 
protein oriented up-up-down-down with two overhand loops connecting the first 
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two and last two helices.30 The C-terminal part of TPO protein bears no 
resemblance to any known proteins.  
Liver is the main site to produce TPO though a tiny amount of it can also be 
generated in kidneys, bone marrow stromal cells and other organs. The 
production of TPO is constitutive and the regulation of TPO levels in circulation is 
dependant mainly on the amount of its receptor c-MPL that is specifically 
expressed on the surface of platelets. By binding to c-MPL, TPO is internalized 
and consumed.31,32 TPO serum concentration was shown being correlated 
inversely with platelet count.33,34 An alternative mechanism for regulating TPO is 
that TPO mRNA production, instead of being constitutive, is up-regulated by low 
platelets events. Increased TPO mRNA in bone marrow was observed in mice 
made severely thrombocytopenic.35 Although TPO production in liver was not 
altered in response to changes in platelet counts in peripheral blood, hepatic 
TPO mRNA levels increased in the presence of the inflammatory mediator 
interleukin-6 (IL-6).36 Thus, the regulation of TPO production and levels may be 
more complex than only one mechanism. 
The gene encoding the TPO receptor, c-MPL, is located on human chromosome 
1p34 consisting of 12 exons.37 Unlike the TPO gene, the c-MPL has a relatively 
short 5’UTR. The transcript starts sites are located between 4 and 45 bp 
upstream from the first ATG codon.37 The promoter of c-MPL has consensus 
binding sequences for Ets and GATA transcription factors, which are vital for 
regulating many megakaryocytic specific genes. Variation in splicing results in 4 
distinct MPL mRNA species in human. The predominant form (P-form) encodes 
the full-length protein. MPL-K (K-form) is due to a read through beyond the 
exon10 splice donor site, resulting a protein different from native MPL since the 
ninth cytoplasmic amino acid with additional 66 amino acids encoded by intron 
10.9 The third variant, MPL-del, arises from alternative splicing between exon 8 
and 9 and encodes a protein with an inframe deletion of 24 amino acids.38 The 
only variant found in both human and mouse is due to elimination of exon10 and 
thus the juxtamembrane WSXWS motif, the transmembrane domain and the 
initial cytoplasmic domain.9,11,37 Multiple splice forms of the receptor have been 
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described as altered in their biological functions, and could exert regulatory 
effects on the receptors. The isoform c-MPL without exon 10 was found able to 
promote degradation of the P-form receptor rapidly when coexpressing both 
receptors.39 However, physiological functions in the regulation of TPO signaling 
have not yet been demonstrated for the various isoforms.  
As a member of the type I hematopoietic growth factor receptor family, c-MPL is 
a homodimer of a single receptor which is composed of a cytokine receptor motif, 
a transmembrane domain and an intracellular domain containing short 
sequences that bind intracellular kinases and other signal-transducing molecules. 
Upon ligand binding, c-MPL receptor undergoes conformational changes by 
bringing the cytoplasmic domains near to each other to initiate many biochemical 
activities. Members of the Janus kinase (JAK) family bind the cytoplasmic 
domains of c-MPL constitutively even in the inactive state. Upon TPO binding, 
JAK kinases, predominately JAK2, phosphorylate tyrosine residues in the 
receptor itself as well as downstream signal transducers and activators of 
transcription (STATs), phosphoinositide-3 kinase (PI3K), and the mitogen-
activated protein kinases (MAPKs) to promote cell survival and proliferation. 
Meanwhile JAK2 also activates molecles that limit cell signaling such as the SH2-
domain-containing protein tyrosine phosphatase 1 (SHP1), SH2-containing 
inositol phosphatase 1 (SHIP1) and suppressors of cytokine signaling (SOCSs). 
An acquired somatic mutation V617F in JAK2 was found in the majority of 
patients with chronic myeloproliferative disorders (MPD), especially in patients 
with polycythemia vera (PV).40-45 This mutation is located at the pseudokinase 
domain of JAK2, which is the negative regulatory domain for the kinase activity.46 
Mutant JAK2 causes cytokine-independent activation of the downstream 
pathways including JAK-STAT and PI3K, MAPKs pathways, which lead to 
overproduction of platelets and erythrocytes in MPD patients.41-45 
Numerous mutations including either homozygous or heterozygous, missense or 
nonsense mutations in the c-MPL gene were identified in congenital 
amegakaryocytic thrombocytopenia, which lead to the loss of function of the 
receptor.47-49 Patients with severe thrombocytopenia carrying homozygous 
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mutant alleles can develop aplastic anemia due to stem cell exhaustion. The only 
treatment for the disease is stem cell transplantation.50 In addition to loss-of-
function, an activating missense mutation in the transmembrane domain of c-
MPL leads to TPO-independent signaling activation, which is the cause for 
hereditary thrombocytopenia in several families.51,52 Interestingly, this mutation 
was first discovered by random mutagenesis of mouse c-MPL.53 Mutations in the 
juxtamembrane domain of c-MPL have been found in patients with MPD, in 
particular idiopathic myelofibrosis (IMF) and ET.54,55 These findings support the 
concept that the membrane-proximal and transmembrane domains are 
constitutively active but blocked by the membrane-distal domains of the receptor. 
TPO binding relieves the blocking and therefore activates TPO/c-MPL signaling 
transduction.   
 
Other growth factors in megakaryopoiesis  
Besides the major regulator TPO, many other growth factors are involved in 
megakaryocyte growth, such as granulocyte-macrophage colony-stimulating 
factor (GM-CSF), IL-3, IL-6, IL-11, stem cell factor (SCF), FLT ligand, fibroblast 
growth factor (FGF), and EPO. These factors either stimulate megakaryocyte 
growth alone or cooperate with TPO. Unlike TPO, which supports the entire 
process of megakaryopoiesis, these cytokines play roles mostly in the early 
stage of megakaryocyte lineage development. Several cytokines are known to 
inhibit megakaryocyte development, such as IL-4,56 transforming growth factor-
?157 and Src kinase inhibitors.58,59 
 
Transcription factors regulating megakaryopoiesis  
Several transcription factors, including GATA-1, acute myeloid leukemia/ runt-
related transcription factor 1 (AML/RUNX1) and nuclear factor-erythroid 2 (NF-
E2), have been shown to play an important role in megakaryocyte development 
by activating megakaryocyte-specific genes and repressing genes for other cell 
lineages. GATA-1 recognizes and binds the sequence (A/T)GATA(A/G) in the 
cis-regulatory elements of many lineage-restricted genes. It interacts with the 
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cofactor friend of GATA-1 (FOG-1) and plays an essential role in early stage of 
megakaryocyte development, where it is involved in lineage commitment of 
megakaryocytes as well as erythrocytes. GATA-1 also functions later in 
megakaryocyte development and proliferation.60 The megakaryocyte-specific 
knockout of GATA-1 results in thrombocytopenia and increased number of 
immature megakaryocytes with small sizes and decreased polyploidization.61 
Located on the X chromosome in humans, missense mutations of GATA-1 lead 
to severe congenital X-linked thrombocytopenia due to disruption between 
GATA-1 and FOG resulting in arrest of megakaryocyte maturation.62,63 
RUNX-1 is an important transcription factor for the development of all 
hematopoietic lineages. It forms a complex with the core binding factor ? subunit, 
which binds the N-terminal domain of GATA-1 and enables the programming of 
megakaryocyte lineage commitment.64 Chromosomal translocations in the 
RUNX-1 gene are frequently found in leukemia. Germ-line mutations of RUNX-1 
resulting in monoallelic loss of RUNX complexes are identified in families with 
autosomal dominant familial platelet disorder with multiple platelet defects, 
reduced c-MPL and predisposition to AML.65 
The transcription factor NF-E2 is a heterodimeric leucine zipper transcription 
factor expressed in the erythroid and megakaryocytic lineage as well as in mast 
cells. It has been shown that NF-E2 controls terminal megakaryocyte maturation, 
proplatelet formation and platelet release by regulating target genes such as ?-
tubulin, thromboxane synthase, Rab27b and possibly some as yet unknown 
target genes.66-69 NF-E2 null mice have neonatal lethality due to severe 
thrombocytopenia with arrest of megakaryocyte maturation, disorganized internal 
membranes and reduced granule numbers in the cells.70 Compound 
homozygous mutation of NF-E2 in mice result in profound impairment of 
megakaryopoiesis.71   
 
Platelet biogenesis 
The terminal phase of megakaryocyte maturation is to generate platelets, which 
is a complex process orchestrated by numerous transcription factors, signaling 
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molecules and cytoskeletal elements. In order to tailor their cytoplasm and 
membrane systems for platelet production, megakaryocytes enlarge themselves 
by multiple rounds of endomitosis, a process that amplifies the DNA contents as 
much as 64 fold without any cell division.72 During endomitosis, mitotic spindles 
assemble but fail to separate. Nuclear envelopes break down and reform to 
generate a polyploid, multilobed nucleus with up to 128n DNA content in mature 
megakaryocytes.73,74 Besides DNA content expansion, internal membrane 
systems, granules and organelles are assembled in bulk during megakaryocyte 
development. An expansive and interconnected membrane network of cisternae 
and tubules called the demarcation membrane system (DMS) is formed and 
serves as a membrane reservoir for the formation of proplatelets, the precursor 
of platelets. The initial model of platelets coming from fragmentation of 
megakaryocyte extensions was brought up a century ago,75 but little was known 
about the details of platelet assembly. The cloning of TPO and its receptor c-MPL 
has allowed major advances in the study of thrombopiesis.76 With stimulation of 
TPO megakaryocytes cultured in vitro become a useful system to study the 
platelet formation process. It has been shown that megakaryocytes cultured in 
the presence of TPO extend numerous proplatelets, from which platelets are 
shed. Both proplatelets and platelets produced in vitro show similar structure and 
function with those generated in vivo.77,78 The proplatelet formation process 
normally starts from one point on the megakaryocyte where pseudopodia form 
and continue to elongate until they become narrowed into proplatelets. A 
proplatelet appears as a thin cytoplasmic string containing multiple bulges similar 
in size to a platelet. Megakaryocytes continue to generate proplatelets from the 
original site and spread this event throughout the rest of the cell until the 
megakaryocyte cytoplasm is totally transformed into a network of interconnected 
proplatelets.79 Platelets are assembled and released from the swellings at the 
proplatelet ends, but the details involved in this event have not been 
characterized.  
Microtubules are the major structural component that drives the elongation of 
proplatelets, which were shown to be filled with microtubules bundles.69 
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Transgenic mice lacking ?1-tubulin, the most abundant platelet ?-tubulin isoform, 
develop thrombocytopenia and have spherocytic circulating platelets.80 A double-
nucleotide mutation resulting in the substitution of a conserved glutamine with a 
proline (Q43P) has been described in the ?1-tubulin gene.81 Individuals carrying 
a heterozygous Q43P mutation showed reduced expression of ?1-tubulin in 
platelets, which were enlarged and spherocytic due to defects in the microtubule 
marginal band. The Q43P mutation is present in about 10% of the normal 
population and has a protective effect against cardiovascular disease.81 
Several disorders of inappropriate platelet production have been identified 
harboring genetic mutations within genes that are active during the process of 
platelet biogenesis. For example, mutations in genes encoding glycoproteins 
have been identified in Bernard-Soulier syndrome, which is an autosomal 
dominant disorder characterized by macrothrombocytopenia, increased bleeding 
time and impaired platelet agglutination. Since glycoprotein complexes are linked 
to the membrane skeleton, it is believed that the genetic defects may alter normal 
cytoskeletal dynamics during platelet formation.82 In a series of MYH9-related 
disorders, numerous mutations have been found in the MYH9 gene, which 
encodes nonmuscle myosin heavy chain IIA, the key myosin isoform expressed 
in platelets. The thrombocytopenia phenotype in MYH9-related disorders is 
thought to be due to defective platelet production as well because both 
megakaryocyte numbers and platelet clearance are normal.83 It has been shown 
that in MYH9-related disorders, a greater amount of myosin is associated with 
the actin cytoskeleton in resting platelets and upon activation mutant platelets 
have altered cytoskeletal dynamics.84 Although these disorders are very rare in 
the general population, identifications of the precise genetic lesions for such 
disorders give further insights into the mechanisms of platelet formation. 
Recently, mice with MYH9 knockout in megakaryocytes were generated and 
displayed macrothrombocytopenia with strong increase in bleeding time and 
absence of clot retraction.85 
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Erythropoiesis 
Erythrocytes are non-nucleated cells without any organelles or RNA, whose 
major function is to carry oxygen to the tissues and bring carbon dioxide back to 
the lung. It is a biconcave-like disk in shape and flexible to pass through the 
microcirculation that is even narrower than the cell’s diameter. The major 
component of erythrocytes is a highly specialized protein, hemoglobin, which 
loads and unloads oxygen. The average lifespan of an erythrocyte in circulation 
is about 120 days, and each day around 1012 erythrocytes need to be made to 
maintain the homeostasis in cell number by the complex and well-regulated 
process of erythropoiesis.  
 
Erythropoietin and Erythropoietin receptor  
Erythropoietin (EPO) is the major cytokine involved in the control of 
erythropoiesis. The receptor for EPO  (EPOR) is increasingly expressed with the 
development of erythroid progenitors and the interaction with its ligand EPO 
activates erythrocytes differentiation and proliferation. Knockout of EPO or EPOR 
in mice leads to lethal anemia at day 12.5 of embryonic life, indicating the crucial 
role of the ligand and receptor interaction that is indispensable for erythropoiesis 
in vivo. However a normal number of erythroid progenitors is present in the fetal 
liver, suggesting that EPO and its receptor are not required for the commitment 
of hematopoietic stem cells to the erythroid lineage.86 
Although the idea of a hormonal substance existing in serum for regulation of 
erythropoiesis87 was long known, purification of EPO was extremely difficult due 
to its low concentration in serum.88 Instead, Goldwasser et al purified EPO from 
human urine successfully.89 The pure urinary EPO enabled the identification of 
amino acid sequences for the protein and subsequently the isolation of the 
human EPO gene.90,91 Human EPO is an acidic glycoprotein with a molecular 
weight of 30.4 kDa that is secreted mainly from kidney and fetal liver.  
The human EPO gene is located at chromosome 7q11-q22 with 5 exons 
encoding a 193 amino acid protein for the prohormone.91-94 27 amino acids are 
cleaved before secretion,95 and the C-terminal arginine that is expected from the 
 17
mRNA sequence is absent in the circulating EPO. Therefore the peptide core of 
human mature EPO is composed of 165 amino acids, which form two bisulphide 
bridges. EPO gene expression is regulated by several transcription factors. The 
promoter region contains binding sites for GATA and nuclear factor ?B (NF-
?B).96,97 GATA-4 is assumed to recruit chromatin-modifying activity and promote 
EPO expression,98 while GATA-2 and NF-?B are thought to be responsible for 
the inhibition of EPO gene expression in inflammatory diseases.99-101 Another 
important regulator for EPO expression is hypoxia-inducible transcription factor 
(HIF), which binds to the hypoxia response elements (HRE) in the 3’ enhancer 
region of the EPO gene. HIF and HRE not only regulate EPO expression but also 
many other hypoxia inducible genes. More than 100 genes have been identified 
that are regulated by HIF-binding to HRE, including the vascular endothelial 
growth factor (VEGF), the glucose transporters and a few glycolytic enzymes.102-
104 
EPO was found binding to a transmembrane receptor of its target cells, EPO 
receptor (EPOR),105,106 which was identified as a member of cytokine class I 
receptor family characterized by an extracellular N-terminal domain, a single 
hydrophobic transmembrane segment and a cytosolic domain without enzymatic 
activity.107,108 The human EPOR gene is located on chromosome 19 with 12 
exons encoding a 484-amino acid glycoprotein. The inactive EPOR is believed to 
be in an unliganded, dimeric state. Upon EPO binding, two EPOR molecules 
connect tightly to each other and undergo a conformational change,109-111 Two 
JAK2 molecules associated with the cytoplasmic region of EPOR are activated 
and thereby several tyrosine residues of the EPOR are phosphorylated to 
provide docking sites for signaling molecules including PI-3K/Akt, STAT5, MAP 
kinase and protein kinase C. De-phosphorylation of JAK2 by the hematopoietic 
cell phosphatase terminates the effect of EPO. EPOR gene mutations resulting in 
the trunction of the receptor at its C-terminal lead to erythrocytosis.112 The 
trunctated EPOR contains the binding site for SHP-1 phosphatase, which is a 
negative regulator of EPOR signaling.112 SHP-1 dephosphalates a number of 
cytoplasmic substrates such as JAK2 and STAT5 to terminate the proliferative 
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signal. The lack of SHP-1 binding results in prolonged STAT5 and JAK2 
activation observed in cell lines expressing truncated EPORs.112   
 
Hypoxia induction of EPO 
The primary function of circulating EPO is to maintain the hemoglobin 
concentration in the normal range. However the levels of hemoglobin or 
erythrocytes do not directly regulate the concentration of circulating EPO. 
Instead, the controlling variable is the tissue oxygen pressure (pO2), which is 
dependent on the hemoglobin concentration, the arterial pO2, the oxygen affinity 
of the hemoglobin and the rate of blood flow. In kidney, the major organ secreting 
EPO, pO2 is hardly affected by the rate of blood flow as the renal oxygen 
consumption changes in proportion with the glomerular filtration rate.113 The 
molecular mechanism of oxygen sensing became clearer since the identification 
of HIF-1, which is the major transcription factor controlling EPO gene 
transcription.114,115 HIF-1 is a heterodimeric protein containing a ? subunit and a 
? subunit. Both HIF-1? and HIF-1? are constitutively translated, but HIF-1? is not 
detectable in normoxic cells due to ubiquitin-mediated degradation of the protein 
in the presence of oxygen.116,117 A critical residue of proline in the C-terminal part 
of HIF-1? is hydroxylated, which is catalysed by specific prolyl hydroxylases 
(PHD1, 2 and 3).118-122 Hydoxylated HIF-1? combines with the von Hippel-Lindau 
tumor suppressor (VHL) to form a protein complex called E3 ligase that 
polyubiquitinate HIF-1? protein, 117,123,124 and then it undergoes proteasomal 
degradation rapidly in the condition of normoxia.125 The PHDs are oxygen 
sensors because their activities depend on the availability of oxygen. Under 
hypoxia, PHDs’ activity is greatly decreased and the proline residues are no 
longer hydroxylated, therefore HIF-1? can accumulate to activate the EPO gene 
and many other genes’ expression. The transcriptional activity of HIFs is also 
regulated by another oxygen-liable hydroxylation at an asparagine residue 
catalysed by a HIF-specific asparaginyl hydroxylase that is termed factor-
inhibiting HIF-1 (FIH-1).126,127 Upon hydroxylation, binding of the transcriptional 
co-activator CAMP response element-binding protein (CREB)-binding protein 
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(CBP)/p300 to the C-terminal transactivation domain of HIF-1? is prevented, thus 
the transcriptional activity of HIF-1 is suppressed.128 Like the PHDs, FIH-1 also 
requires oxygen for its function, together these hydroxylases serve as cellular 
oxygen sensors.  
Two isoforms of HIF-? have been identified, namely HIF-2? and HIF-3?.129-132 
Both isoforms are oxygen-dependent and can form the heterodimer with HIF-1? 
in hypoxia but are different with respect to their tissue-specific mRNA expression 
pattern.133 HIF-2? is expressed in renal fibroblasts while tubular cells express 
HIF-1?.134 Recent studies indicate that HIF-2? is the primary transcription factor 
inducing EPO gene expression.135 In contrast to HIF-1? and HIF-2?, HIF-3? is 
lacking a transcriptional activation domain and can suppress the expression of 
hypoxia inducible genes.136  
Genetic defects in any components in the hypoxia sensing pathway could lead to 
overproduction of EPO protein and thereafter erythrocytosis. An arginine to 
tryptophon substitution at amino acid position 200 of VHL protein causes 
Chuvash polycythemia, which is an inherited endemic polycythemia occurred 
mainly in patients from Chuvashia.137 The mutation in VHL protein impairs the 
interaction of VHL and HIF-1?, reducing the degradation rate of HIF-1? thus 
leads to increased expression of EPO and many other downstream target genes.  
A germ-line mutation in PHD2 was also found in a family with moderate 
erythrocytosis.138 
 
Familial Myeloproliferative disorders 
Myeloproliferative disorders (MPDs) are a group of clonal hematological 
malignancies characterized by aberrant proliferation of one or more myeloid 
lineages, which contains three subtypes: polycythemia vera (PV), essential 
thrombocythemia (ET) and idiopathic myelofirosis (IMF). Though the etiology for 
MPD remained unclear for long, it was believed that acquired somatic mutations 
occurred in hematopoietic progenitors or stem cells lead to over proliferation of 
the mutant cells thereby causing the disease. Recently-identified somatic 
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mutations in JAK2, which are prevalent in sporadic MPD patients,40-45 are 
reshaping the molecular studies for MPD.   
Familial forms of MPD, though showing similar symptoms that are sometimes 
indistinguishable from sporadic patients clinically, have different pathogenesis 
from sporadic MPD. Familial MPDs are polyclonal and caused by germ-line 
mutations inherited in the Mendelian way among family members. Searching for 
molecular alterations using linkage analysis has been very successful in some 
families with hereditary thrombocythemia (HT) and with primary familial and 
congenital polycythemia (PFCP). Five mutations in the TPO gene have been 
identified in HT families and all are located in the 5’UTR of the gene, causing 
increased translation efficiency of TPO protein.21-27 One missense mutation was 
identified in the MPL transmembrane domain in 5 HT families, which leads to a 
hyperactive receptor activating downstream signals to stimulate cell 
proliferation.51,52 Nine mutations have been described causing PFCP (reviewed 
in 139). All these mutations lead to truncations of the cytoplasmic domain of the 
EPOR, which is a negative regulatory domain for the receptor. Truncated 
receptor therefore is hypersensitive to EPO and stimulates EPO-mediated signal 
transduction. None of these mutations in TPO, MPL or EPOR are found in 
sporadic MPD patients,140-142 indicating these mutations are relatively rare events 
that only occur to certain families. In addition, these mutations only account for a 
small part of families with familial MPD, and the disease-causing gene(s) in many 
other families remain to be clarified.143-145 It is reasonable to assume that some 
unknown germ-line mutations or polymorphisms could facilitate somatic 
mutations that lead to developing MPD in sporadic patients. Familial MPDs offer 
us a useful tool for searching for such molecular alterations using genetic 
approaches.  
Identification of the germ-line mutations in familial MPDs has made the disease-
causing genes such as TPO and MPL top candidate genes for sequencing in 
newly studied MPD families with unknown pathogenesis. In addition, studies on 
familial MPDs contribute to our understanding of the regulatory mechanism of 
thrombopoiesis and erythropoiesis.    
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Genetic approaches to identify human disease genes 
Genetic studies have made remarkable contributions to the understanding of 
human diseases. A candidate gene approach led to discovery of many disease-
causing genes based on previous knowledge and educated guesses. More often, 
when the pathogenesis for one disease is unknown or candidate genes have 
been excluded, a genome-wide screen for the disease gene is indispensable.   
However this genome-wide screen had rare successes for a long time because 
there was limited information on the human genome. With the development of 
the human and other genome projects, a vast range of resources of maps, 
clones, sequences, expression data and phenotypic data became available. 
Together with the technology for genotyping large amount of markers and 
mutation screening, identifying novel disease genes has become commonplace 
and is currently occurring frequently. The basic procedure for identifying human 
disease genes in family linkage studies is summarized in Figure 1, even though 
in practise there is no standard route and every step is affected by experimental 
results.  
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Figure 1 How to identify a human disease gene. Though no standard pathway to 
success, the key step is to arrive at certain plausible candidate gene, which can then be tested 
for functional alterations in affected individuals. Interplay between clinical work, laboratory 
benchwork and computer analysis is important for a success in identifying a disease gene.  
 
 
Linkage studies 
Many genes causing Mendelian diseases have been discovered by linkage 
studies using families with multiple affected individuals. With the early progress 
of the Human Genome Project, over ten thousand highly polymorphic genetic 
markers have been found and placed on framework maps,146,147 which enable a 
higher resolution genome-wide mapping in family linkage studies.  
The principle of linkage studies is based on the fact that recombination rarely 
occurs between two loci that are close to each other on the same chromosome. 
By searching for genetic markers segregating with the disease phenotype 
inherited through generations in a family, the disease gene can be tracked down 
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since it is close to the marker’s location. Theoretically any Mendelian character 
that can distinguish the paternal and maternal allele in one individual can be 
used as a genetic marker. It is crucial, however, for genetic markers to be 
sufficiently polymorphic and densely located throughout the whole genome 
(<20cM). The first generation of genetic markers was restriction fragment length 
polymorphism (RFLP). The limitation of RFLPs is that they have only two alleles: 
the site is present or it is absent. Disease mapping using RFLPs could be 
frustrating because very often a key meiosis in a family turns out to be 
uninformative. Microsatellite markers were a great improvement since they have 
multiple alleles and high heterozygosity. Most meioses are informative within a 
family. PCR using microsatellites make linkage analysis fast and easy. Moreover, 
many compatible sets of microsatellite markers have been developed that can 
cover the whole genome with 400 markers. Microsatellite markers remained the 
most commonly used genetic markers for linkage studies until the recent launch 
of gene chip technology that can integrate thousands of SNPs in one single chip 
and genotype them at once. SNPs, as bi-allelic markers, have lower 
informativeness than microsatellite markers. However the large amount of SNPs 
that can genotype in chips make them very powerful and they are replacing the 
microsatellites rapidly in genetic linkage and association studies nowadays. 
There are two types of linkage analyses: parametric and nonparametric linkage 
analysis. Parametric linkage analysis requires a precise genetic model including 
the mode of inheritance, the disease penetrance and the allele frequencies. As 
long as a valid model is available, parametric linkage should be applied since it 
provides the most powerful method to locate a disease gene. For some 
Mendelian characters, to ascertain a clear-cut pedigree is normally easy. For 
nonmendelian conditions, however, it is much less tractable. An incorrect genetic 
model can corrupt linkage analysis and mislead the follow-up studies. Therefore 
nonparametric linkage analysis is recommended in such cases. Nonparametric 
linkage analysis, also named model-free or allele-sharing analysis, ignores 
unaffected people, and looks for alleles or chromosomal segments that are 
shared by affected individuals within a family. Without making any assumptions 
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about the genetics of the disease, it has been used as the main tool for studying 
common nonmendelian diseases such as diabetes and schizophrenia. However 
nonparametric methods decrease the power of mapping, candidate regions 
defined by this method are usually large.  
Linkage studies using families discovered many genes for Mendelian diseases, 
but have only limited success in finding genes for complex diseases such as 
diabetes, asthma and heart disease. With the rapid progress of genotyping 
technology, association studies become a powerful and preferable method for 
mapping complex diseases.  
  
Association studies 
In association studies, a large number of SNPs, either for the whole genome or in 
candidate linkage regions, are genotyped in a large group of unrelated people 
and a statistical analysis is performed to detect the co-occurrence of certain 
alleles and the disease.  For example allele A is associated with disease D if 
people who have D also have A more (or maybe less) often than would be 
predicted from the individual frequencies of D and A in the population.  Two 
different designs can be used in association studies: the population-based 
method that uses unrelated individuals and the family-based method that uses 
numerous families sharing the same disease. Genetic association studies have 
increasingly reported positive results, but many of them could not be 
replicated.148 With the huge amount of information from genome-wide association 
studies, it becomes more and more challenging to interpret the data genetically 
and statistically.  
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RESULTS I: 
 
 
Mutations of thrombopoietin and MPL gene in hereditary 
thrombocythemia 
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Abstract  
 
Background and Objectives.  Hereditary thrombocythemia (HT) is an autosomal 
dominant disorder with clinical features resembling sporadic essential thrombocythemia 
(ET). Germ line mutations in HT families have been identified in the genes for 
thrombopoietin (THPO) and its receptor, MPL. Here we characterized a THPO gene 
mutation in a HT pedigree with 11 affected family members. 
Design and Methods. Linkage analysis was performed and the THPO gene was 
sequenced. Thrombopoietin (TPO) serum concentrations were determined by ELISA. 
The mRNA and protein levels for MPL were assessed by real-time PCR and Western 
blotting, respectively. Haplotype analysis using microsatellites and single nucleotide 
polymorphisms (SNPs) were performed. 
Results. We identified a G?C transversion in the splice donor of intron 3 of the THPO 
gene that co-segregated with thrombocytosis within the pedigree. We have previously 
described the identical mutation in a Dutch HT family. Haplotype analysis using 
microsatellites and SNPs surrounding the mutation provided no evidence for a founder 
effect and indicated that the mutations have arisen independently in the two families. 
MPL protein levels, but not mRNA levels, were low in platelets from affected family 
members. Bone marrow histology showed features compatible with those of ET, but the 
megakaryocytes were unusually compact, as assessed by planimetric analysis. Impaired 
microcirculation resulting in brief episodes of fainting and dizziness that responded well 
to aspirin were the predominant clinical features in a total of 23 affected family members 
studied.  Compared to sporadic ET patients, familial patients have earlier onset ages but 
similar severity of symptoms. 
Conclusions and interpretations.  This is the fifth report of HT family caused by a 
mutation in the THPO gene, yet the first one sharing the same mutation with a family 
reported previously. Patients with overproduction of TPO have a mild phenotype not 
requiring cytoreductive treatment. 
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Introduction 
 
Hereditary thrombocythemia (HT), also known as familial thrombocytosis or familial 
essential thrombocythemia, is an autosomal dominant disorder with clinical features 
resembling sporadic essential thrombocythemia (ET). HT is characterized by active 
proliferation of megakaryocytes and overproduction of platelets. The key regulators for 
platelet production are thrombopoietin (TPO) and its receptor, MPL. To date, four 
different germ line mutations in the thrombopoietin (THPO) gene have been identified 
and all of them alter the 5 prime untranslated region (5’-UTR) of the THPO mRNA, 
which contains open reading frames (ORF) that inhibit the translation of THPO mRNA.21-
27 The mutations remove the inhibitory ORFs and lead to increased translation of the 
THPO mRNA causing elevated TPO serum levels and overproduction of platelets.22,24 A 
missense mutation in the transmembrane domain of MPL has been identified in a HT 
family.51 This mutation generates a hyperactive MPL protein and results in excessive 
platelet production. Recently, mutations in the juxtamembrane domain of MPL have been 
found in patients with chronic myeloproliferative disorders (MPD), in particular 
idiopathic myelofibrosis (IMF) and ET,54,55 but THPO mutations have not been detected 
in patients with sporadic ET.140 In some HT families, both THPO and MPL genes can be 
excluded as the cause of thrombocytosis and thus, other as yet unknown genes can be 
involved in causing an identical phenotype.143,144 
 
In this study, we analyzed a Polish family with HT and identified a G?C transversion at 
the intron 3 splice donor in THPO that co-segregated with the thrombocythemia 
phenotype. This mutation is identical with the mutation we previously described in a 
Dutch family with HT.22 Here we present a comparison of the clinical and 
pathomorphological features of 23 affected family members with 17 sporadic ET patients 
published previously.149 
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Design and methods 
 
Patients and clinical features 
The proposita (PL09) was referred to the hematology clinic at the Ludwik Rydygier 
Memorial District Hospital in Kraków, Poland, in the year 2000 (age at diagnosis = 19 
years) because of significant thrombocytosis (1’455 x 109/L) found in a routine blood 
test. At presentation the patient was asymptomatic and without physical signs.  
Abdominal ultrasound revealed minimal splenomegaly (124 mm in the long axis). The 
peripheral blood values were: platelets 1’032 x 109/L, white blood cells 7 x 109/L; red 
blood cells 5.1 x 1012/L; hemoglobin 13.6 g/dl, hematocrit 39.7 %, MCV 78.5 fl; MCH 
26.9 pg; MCHC 34.2 g/dl. No cause of reactive thrombocytosis was found and the 
histology of the bone marrow was compatible with the diagnosis of MPD other than 
chronic myeloid leukemia, most probably ET. Since the patient fulfilled the 
Polycythemia Vera Study Group (PVSG) and the World Health Organization (WHO) 
criteria for ET,150-154 and her platelet levels on follow up constantly exceeded 1’000 x 
109/L, treatment with hydroxyurea at a dose of 1 g/day was initiated and continued for 
two years. During the two years of hematological follow-up she had been suffering from 
episodes of brief transient unconsciousness, initially interpreted with the aid of 
electroencephalography as epileptic in origin, and treated with carbamazepine for one 
month. After the familial background of the disease became evident, hydroxyurea was 
stopped and treatment was changed to low-dose aspirin (75 mg/d). Currently, she is 
maintained on low-dose aspirin, her platelets are stabilized at levels around 800 x 109/L. 
The spleen is not palpable, and she does not manifest any other signs or symptoms of 
disease. At the end of 2001, thrombocytosis was diagnosed in her two sisters (PL07 and 
PL08). The older sister, PL07, suffered from a Raynauld phenomenon and brief episodes 
of fainting and dizziness. In addition, a persistent pain in her right elbow was noted, 
without any detectable local radiological and vascular abnormalities.  She manifested 
mild splenomegaly (130 mm in the long axis on ultrasound).  She was treated with low-
dose aspirin and ticlopidine, and currently is asymptomatic. At presentation, PL08, the 
dizygotic twin of the proposita, complained of bilateral paresthesia in her fingers, and 
reported an episode of superficial vein thrombosis in her left hand. Treatment with low-
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dose aspirin resulted in complete remission of paresthesia. Her platelets are stable at the 
levels below 700 x 109/L. Soon after, another young thrombocythemic female patient 
(PL04) treated in another institution for headaches, arterial hypertension and obesity, was 
identified as their great-grandparental cousin. Similar to the other family members, her 
symptoms responded to low-dose aspirin. The clinico-pathological picture found in 
several members of the youngest generation prompted a wide screening of their extended 
family, revealing altogether 11 affected family members.  
 
Blood cells separation, DNA and RNA extraction 
Blood cells were separated by standard protocols using Histopaque (Sigma, St. Louis, 
MO, USA) gradient centrifugation. Granulocytes and peripheral blood mononuclear cells 
were collected respectively. Platelets were collected using the Sepharose (Amersham 
Pharmacia Biotech AB, Uppsala, Sweden) gel filtration method.155 DNA was extracted 
using a standard proteinase K (Promega, Madison, WI, USA)/phenol (Fluka Chemie AG, 
Buchs, Switzerland) extraction protocol. RNA isolation was carried out using the TRIfast 
reagent (peqLab Biotechnology GmbH, Erlangen, Germany).  
 
Pathology of bone marrow 
Trephine bone marrow biopsies of anterior superior iliac crest were obtained for the 
diagnostic purposes in five members of the family after their informed consent. Tissue 
cores were fixed in 4% buffered formaldehyde, decalcified in hydrochloric acid-based 
commercial solution (Shandon TBD-1 Rapid Decalcifier, Anatomical Pathology 
International, Runcorn, UK), embedded in paraffin and cut into 4 μm sections.  The 
dewaxed slides were stained with hematoxylin and eosin (H&E), periodic acid-Schiff, 
Giemsa, and Gomori silver for reticulin fibers. Bone marrow fibrosis was quantitated in a 
scale ranging from 0 to +4.156 Accessory immunostaining encompassed CD61 and CD34 
(both from DakoCytomation, Glostrup, Denmark) used to highlight atypical and 
particularly small megakaryocytes, and to visualize blasts, respectively.  Objective, 
computer-assisted analysis of megakaryocyte planimetric parameters was performed on 
the H&E sections as described previously.157 Briefly, the high-power/high-resolution 
electronic images of representative megakaryocytes were transformed into two-color 
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bitmaps depicting the cytoplasmic and nuclear shapes.  These were analyzed in respect to 
a series of standard planimetric parameters (linear sizes, areas, shape factors, etc) using a 
computer image analysis system Analysis pro v. 3.2 (Soft Imaging System GmbH, 
Münster, Germany).  The results were compared to the analogous parameters 
characterizing representative megakaryocytes in 10 control trephines demonstrating 
normal marrows and 20 cases of classical sporadic essential thrombocythemia, diagnosed 
according to the WHO criteria.152,153 
 
Quantitative PCR for PRV-1and MPL 
Total RNA (2 μg) was reverse transcribed after random hexamer priming. The primers 
for ribosomal protein L19 (RPL19), MPL and polycythemia rubra vera-1 (PRV-1) were 
designed across exon-intron junctions. The primers for RPL19 were 
GATGCCGGAAAAACACCTTG, TGGCTGTACCCTTCCGCTT, 
CCTATGCCCATGTGCCTGCCCTT (probe); for PRV-1: CCCCAGCAGACCCAGGA, 
TTGTCCCCTCCAGACAGCC, CCATAGACAAGCAGACTGGGCACCTCAA 
(probe). The probes were dual-labeled with 5’-6-carboxyfluorescein (FAM) and 3’-
tetramethyl-6-carboxyrhodamine (TAMRA). The SYBR detection primers for MPL were 
AGCCCTGAGCCCGCC and TCCACTTCTTCACAGGTATCTGAGA. The ?CT 
values were derived by subtracting the threshold cycle (CT) values for PRV-1 and MPL 
from the CT value for RPL19, which served as an internal control.
158 A non-affected 
family member PL15 was chosen as a calibrator for calculating the ??CT values.159,160 All 
reactions were run in duplicates using the ABI 7000 Sequence Detection System  
(Applied Biosystems, Foster City, CA, USA).  
 
EEC assay 
The clonogenic cultures for erythropoietin-independent colony formation  (EEC assay) 
were performed as previously described using commercial reagents Methocult H4531 
(Stem Cell Technologies Inc, Vancouver, BC, Canada). 158 
 
Analysis of genetic linkage 
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DNAs were PCR amplified using dye-labeled primers for microsatellite markers. The 
PCR program includes at 94ºC for 15 sec, 55ºC for 15 sec, 72ºC for 30 sec for 10 cycles, 
89ºC for 15 sec, 55º for 15 sec and 72ºC for 30 sec for 20 cycles. The PCR products were 
analyzed using ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s protocol. Genotypes were scored using the Genemapper 
software package version 3.5 (Applied Biosystems, Foster City, CA, USA) and linkage 
analysis was carried out with FASTLINK software package version 4.1p. Equal allele 
frequencies for the marker alleles were assumed. An autosomal dominant inheritance 
model with a 100% penetrance was used. 
 
Genomic DNA sequencing 
The entire coding region including intron/exon boundaries of the THPO gene was 
sequenced from PCR fragments, amplified from genomic DNA of the affected family 
member PL10. The primer sequences for PCR are shown in Supplementary Table 1. The 
PCR conditions were 95ºC for 2 min, 94ºC for 30 sec, 58ºC for 30 sec and 72ºC for 1 min 
for 35 cycles. Sequencing was performed on an Applied Biosystems 3700 DNA 
sequencer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
protocols.  
 
RFLP analysis.  
For co-segregation analysis, a 951 bp PCR fragment was amplified using the primers 
AGCCTAAGCCGCCTCCATG (exon 3, sense) and GGTGGCCAAGCTGAAGGTG 
(intron 5, antisense) from genomic DNA of all family members and digested with Bsr I 
restriction enzyme at 65ºC overnight. Fragments of 460 bp for the mutant allele and 359 
bp for the normal allele were visualized by ethidium-bromide staining after agarose gel 
electrophoresis.  
 
Haplotype analysis 
To determine the founder effect, 6 microsatellite markers located in the vicinity of the 
THPO gene were chosen for linkage analysis. Sequences of the primers are provided in 
Supplementary Table 2. The PCR products were analyzed as described above. The 
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haplotypes were determined based on the segregation within the pedigrees and the sizes 
of the PCR products of the co-segregating microsatellite markers were compared between 
affected members of the two families. Ten SNPs located within the THPO gene 
(Supplementary Table 3) were selected from the dbSNP at the NCBI homepage 
(http://www.ncbi.nlm.gov/projects/snp/) and genotyped by sequencing.  
 
Human TPO ELISA and immunoblot assay of MPL  
TPO serum levels were measured using the TPO-Quantikine ELISA (enzyme-linked 
immunosorbent assay) kit (R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s protocol. MPL protein expression in platelets was determined by 
immunoblot analysis using the polyclonal rabbit antibody (CTP7) specific for the C-
terminus of human MPL (kindly provided by Dr. Jerry L. Spivak, John Hopkins 
University, Baltimore).  The membranes were re-probed using a monoclonal antibody 
against human CD61 (BD Biosciences, San Jose, CA, USA) serving as a loading control.  
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Results 
The clinical features of 11 family members with thrombocytosis are summarized (Table 
1). Thrombocytosis in many of the patients was detected in childhood or adolescence. 
Five of the 11 affected family members had symptoms that are potentially related to 
thrombocytosis, including hypertension, headaches, Raynauld phenomenon, limb 
paresthesia, venous thrombosis, transient ischemic attacks, miscarriage and Buerger 
disease. Most of these symptoms, except Buerger disease, were manageable using low-
dose aspirin. In contrast, attempts to relieve the symptoms by cytoreductive therapy with 
hydroxyurea were ineffective. Patient PL13 died of thromboembolic complications of his 
Buerger disease at age 57.  
 
Linkage analysis revealed co-segregation of thrombocytosis with two microsatellite 
markers (THPO1 and THPO2) located in close vicinity of the THPO locus with a 
logarithm of odds (LOD) score of 3.3 at theta = 0 (data not shown). Sequencing of the 
THPO coding region as well as the intron-exon boundaries revealed a G?C transversion 
in the splice donor of intron 3 (Figure 1A). This mutation alters a BsrI restriction site and 
produces a restriction fragment length polymorphism (RFLP), which was used to confirm 
Table 1 Summary of clinical data of 11 members of the Polish family with
thrombocytosis.
UPN Sex Date
of
Birth
Date of
Dx
Date of
last
follow
up or
DOD
Platelets
150-450
x109/L
WBC
3.5-10.0
x109/L
(2003)
RBC
4.2-6.3
x1012/L
(2003)
Hemo-
globin
12-14 F
14-18 M
g/L
(2003)
Spleno-
megaly
(last
follow
up)
Hepato-
megaly
(last
follow
up)
Thrombocytosis-
associated symptoms
Important
co-
morbidity
PL02 F 1956 3/200 3 3/2003 545-560 5.9 4.5 131 na na none not known
PL04 F 1986 8/2001 6/2006 595-1300 8.1 4.7 123 (+) (-) hypertension
headaches
obesity
PL06 M 1950 3/2003 3/2006 408-420 6.5 5.0 145 (-) (-) none none
PL07 F 1978 10/2001 9/2005 760-960 6.1 4.7 132 (+) (-) Raynauld phenomenon
transient ischemic attacks
miscarriage
persistent
pain in the
right elbow
PL08 F 1982 10/2001 92004 750-890 7.1 4.7 135 (-) (-) limb paresthesia
venous thrombosis
none
PL09 F 1982 11/2000 12/2005 740-1340 6.7 4.1 127 (-) (-) transient ischemic attacks
PL10 F 1991 3/2003 3/2003 960 10.6 5.2 142 na na none
PL11 F 1922 3/2003 3/2003 510 7.7 5.0 150 na na na
PL12 M 1947 10/1998 3/2003 550-560 5.3 5.5 156 (+) na melanoma
PL13 M 1948 3/2003 4/2003 910 -
1190
10.7 4.7 139 (+) (-) Buerger disease,
died in 2005
viral
hepatitis
type B
PL14 M 1992 3/2003 3/2003 460 6.2 4.6 123 na na na
UPN, unique patient number; Dx, diagnosis; DOD, date of death; WBC, white blood cells; RBC, red blood
cells; lowest and highest values are given where available; Dx, diagnosis; na, data not available
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the co-segregation of the mutation within the pedigree (Figure 1B). We previously 
described the identical mutation in a Dutch family with thrombocytosis. 22 This mutation 
destroys the splice donor site in intron 3 and results in exon 3 skipping (Figure 1A). We 
have shown that the resulting shortened 5’-UTR leads to overproduction of TPO protein 
by a mechanism of increased efficiency of THPO mRNA translation.22 The mutation was 
not found in a previously published series of 50 sporadic ET patients.140 Here we 
screened for this mutation in additional 76 sporadic ET patients, but did not find any new 
case (data not shown). 
 
 
Figure 1  The THPO gene mutation. A) The sequencing chromatogram of the boundary 
between THPO exon 3 and intron 3 (dashed vertical line) from an affected individual is 
shown. Arrow points to the G?C transversion in the sequence. The recognition sequence 
for the Bsr I restriction endonuclease is boxed. This recognition sequence is destroyed by 
the G?C transversion. The THPO gene locus is shown below. The asterisk marks the 
position of the G?C transversion. Open boxes represent exons. Exons connected by 
solid lines represent normal splicing and dashed lines indicate expected consequence of 
the THPO mutation on splicing. B) Co-segregation of the THPO mutation and 
thrombocythemia within the pedigree. The Bsr I restriction fragment length 
polymorphism, caused by the presence or absence of the G?C transversion, was used to 
follow the inheritance of the THPO mutation. Individuals within the pedigree are 
positioned above the corresponding lanes.  
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To determine whether the mutation in the two families represents a founder effect or has 
independently arisen de novo, we examined polymorphic DNA sequences in the vicinity 
of the mutation. A founder effect, i.e. descent of both families from a common affected 
ancestor, is expected to result in sharing of allelic sequence polymorphisms in the vicinity 
of the THPO mutation in affected members from both families. First, we compared six 
microsatellite markers located between 4 kb to 40 kb from the THPO mutation, but all 
PCR products that represent the haplotype of the affected allele in the two families 
showed different sizes (Figure 2A), suggesting that the mutation occurred independently 
in these two families. Since the mutation rate of microsatellites is relatively high, in the 
range of 10-3 to 10-4 per locus per generation,161 we cannot exclude that some of the 
differences could be due to the inaccuracy in the replication of repetitive elements. We 
therefore genotyped SNPs, which are genetically more stable and display a lower 
mutation rate (10-8 per generation).162 By screening 10 SNPs located within the THPO 
gene we found that 3 informative SNPs, representing the haplotype of the co-segregating 
mutant allele, differed in their sequences between the two families (Figure 2B). One SNP 
(rs956732) is located only 150 nucleotides upstream of the mutation, while the other 2 
SNPs (rs2280740 and rs10513797) are located 507 and 1’553 nucleotides downstream of 
the mutation, respectively (Figure 2B). Due to the very short physical distance between 
these SNPs and the G?C mutation, it is very unlikely that the differences in the sequence 
between these two families are due to recombination. Therefore, we conclude that the 
mutation in these two families occurred independently and de novo.  
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Figure 2  Haplotype analysis for the THPO locus in the Polish family and the Dutch 
family. A) The chromosomal locus containing the THPO gene is shown. Black boxes 
represent genes: THPO, thrombopoietin; CHRD, chordin; POLR2H, polymerase RNA II 
DNA directed polypeptide H; CLCN2, chloride channel 2. Microsatellite markers are 
shown above the locus, numbers indicate the sizes in nucleotides of the PCR products of 
the co-segregating mutated alleles in the Polish and Dutch families. Note that none of the 
allele sizes are identical in the two families. B) The THPO gene locus with the positions 
of three informative single nucleotide polymorphisms (SNPs) is shown. The sequences at 
each of the SNP positions are shown for the co-segregating mutated allele only. The 
allele frequencies for each SNP are listed below. Note that the sequences of the 3 SNPs 
located in the vicinity of the G?C transversion (black box with white letters) differ in 
the two families. 
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To explore how the THPO mutation affects the regulation of platelet production, we 
measured the TPO serum concentrations and MPL protein expression levels on platelets 
and compared them with the platelet counts in all family members (Figure 3A). Two 
affected family members showed highly elevated serum TPO levels (PL12 and PL13), 
the other 9 affected family members had only slightly elevated or normal TPO serum 
levels. TPO concentrations showed no clear correlations with the platelet counts (Figure 
3A). The MPL protein expression levels were determined in platelet lysates and 
normalized ratios against CD61 were used to determine the relative MPL protein amount. 
Nine of 11 patients showed decreased expression of MPL protein amount compared to 
the normal. Interestingly the individual with the highest TPO serum level had the lowest 
MPL expression (PL12). There were significant differences in mean values for platelet 
counts (p<0.001), serum TPO concentration and MPL protein expression (p<0.05) 
between affected and non-affected family members (Figure 3B). The low amount of MPL 
protein was not due to decreased mRNA levels, as shown by real-time PCR. Rather, there 
was a slight, but non-significant increase in MPL mRNA in the affected individuals 
(Figure 3B). Interestingly PL12, who had the lowest MPL protein level, showed the 
highest MPL mRNA level (Figure 3A), confirming similar data obtained in the Dutch 
family with the same THPO mutation.158 All 11 affected family members had normal 
levels of PRV-1 mRNA in granulocytes and did not display growth of EECs (data not 
shown). 
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Figure 3  The correlations between the platelet count, TPO serum concentration and 
MPL expression. A) The Western blotting of MPL and CD61 protein in platelets are 
shown. The individuals within the pedigree are placed above the corresponding lanes. 
The platelet counts x10
9
/l (plt), the TPO serum concentrations in pg/ml (TPO), the MPL 
mRNA expression determined by real time PCR, and the ratios of MPL protein against 
CD61 determined by densitometry are shown. B) Boxes represent the interquartile range 
that contains 50% of the values, the horizontal line in the box marks the median and bars 
indicate the range of values. P values are calculated by one-side t-test for independent 
samples (* P value < 0.05, ** P value < 0.001). The relative expressions of MPL mRNA 
(??CT values) are shown on a logarithmic scale. The values are relative to a non-affected 
family member PL15. The horizontal bar indicates the median.  
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Since in this family thrombocytosis is caused by a known mechanism, i.e. overproduction 
of TPO protein, it is interesting to compare the histopathology of bone marrow trephines 
from affected family members with trephines from sporadic ET patients. The results of 
the analysis of archival material from 5 affected members of the Polish family and 1 
member of the Dutch family are summarized in Table 2. The megakaryocyte densities 
were comparable to the lower limits of the values encountered in chronic MPDs, but were 
much higher than the appropriate age norms.163,164 The density of megakaryocytes in the 
individual cases did not correlate with the platelet count. The tendency for clustering was 
noticeable, but less then 5% of megakaryocytes participated in the cluster formation. 
Only rarely did the clusters contain more than 3 cells. There was no tendency for 
intrasinusoidal location of megakaryocytes. None of the patients displayed obvious 
atypia, but the megakaryocytes were strikingly compact when compared to normal 
megakaryocytes and particularly to the megakaryocytes of essential thrombocythemia 
(Figure 4). This impression was corroborated by the objective planimetric analysis of 
megakaryocytes, which demonstrated significant differences between these 3 diagnostic 
groups (ANOVA data not shown). Specifically, the cellular regularity may be quantified 
as the cellular compactness factor (CF), representing the ratio of the minimal diameter to 
the maximal diameter of an object, thus ranging from 1 (for a circle) to 0. On the post-
hoc analysis, cellular CF of megakaryocytes in familial thrombocytosis (0,752 ± 0,102) 
significantly surpassed both the controls (0.726 ± 0.111, p = 0.0078) and the essential 
thrombocythemia cases (0.706 ± 0.122, p < 1x10-6). Furthermore, the megakaryocyte 
nuclear CF (0.697 ± 0.116) was significantly higher than in the controls (0.675 ± 0.123, p 
= 0.026), but only marginally and insignificantly higher than in essential 
thrombocythemia (0.686 ± 0.118, p = 0.15).  Most other planimetric parameters, like the 
descriptors of a cellular size, nucleo-cytoplasmic ratio, the degree of nuclear 
segmentation expressed as a number of distinct nuclear fragments per cell, and nuclear 
sizes, corresponded to the values typical for normal megakaryocytes, but not for the 
essential thrombocythemia (data not shown).   
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In 2/5 patients a minor fraction of megakaryocytes expressed CD34 (Table 2). This 
phenomenon is rare in a non-neoplastic setting, although its significance still remains 
unclear. There was no increase or clustering of blasts. Minimal intensification of the 
reticulin fiber meshwork was compatible with the upper limit of the semiquantitative 
norm.156 The distention of sinuses was mild. All the cases showed a slight increase in 
eosinophil granulocytes, a phenomenon not reflected in peripheral blood. The erythroid 
cells in the four younger patients did not form clear-cut islands (erythrons) and in the 
case PL09, the intensified erythropoiesis was dispersed or organized in small clusters.  
There were no features of dyserythropoiesis or dysmyelopoiesis. A paratrabecular rim of 
promyelocytes was preserved. The bone structures, particularly the cortical bone, were 
quite massive (although not sclerotic), which may explain problems in obtaining 
representative trephines in the members of this family. In summary, bone marrow 
histology in the family demonstrated a range of features mimicking a "true" MPD, 
particularly megakaryocytic hyperproliferation and clustering. However the 
megakaryocytic morphology, with their very compact ("hyper-normal") shapes and rather 
normal sizes notably differed from the cytology of this hematopoietic lineage 
characterizing classical ET.   
 
Figure 4 Trephine bone marrow biopsy of 
patient PL08 stained with hematoxylin & 
eosin, showing high marrow cellularity, 
markedly increased number of 
megakaryocytes, their occasional loose 
clustering and moderate increase in dispersed 
mature eosinophils.  Note very regular shapes 
of the megakaryocytes. Original objective 
magnification 60x. 
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We performed a retrospective analysis of the clinical course in affected family members 
of the Polish and Dutch families (Table 1 and Supplementary Table 4). Clinical 
characteristics of the 23 familial patients were compared with 17 sporadic ET patients 
previously published in 2000 (Table 3).149 General characteristics between the two groups 
were comparable, except for age at diagnosis. As expected, familial thrombocytosis 
patients were diagnosed at an earlier age than sporadic ET patients (35 median, range 5- 
81 versus 67 median, range 16-84, p = 0.007). Rates on localization of hemostatic 
complications are summarized in Table 4. Hemorrhage (given as number of events per 
100 patient years) was the only complication that differed significantly between the two 
groups (familial thrombocytosis patients 0.6 events per 100 patient years, essential 
thrombocytosis patients 11.8 events per 100 patient years, p 0.009). Venous 
thromboembloic events (0.6 versus 3.2, p= 0.20) and major vasomotor complications (1.3 
versus 1.1, p= 0.45) were comparable in two groups. Two patients in each group 
developed secondary fibrosis (p value is not significant).  
 
 
 
 
Table 2 Quantitative aspects of bone marrow histology in familial thrombocytosis.
Cellularity
[%]
Megakaryocytes
per mm2UPN Sex Date
of
birth
Year
of
biopsy
Platelets
x109/L
Cases
Age
norm* Cases
Age
norm*
Myeloid/
erythroid
ratio
CD34
blast
cells
Clusters of
megakaryo-
cytes
Increase
in
eosinohils
Reticulin
fibres**
Distended
sinuses
CD34+
megakaryo-
cytes
PL08 F 1982 2001 887 90
72 ±
11
90 16 ± 4 4:1 <1% + + 0 + +
PL09 F 1982 2000 1340 90
72 ±
11
58 16 ± 4 2:1 <1% + + 0/+1 + -
PL07 F 1978 2001 956 80
70 ±
12
60 15 ± 6 3:1 <1% + + +1 + -
PL04 F 1986 2003 868 95
72 ±
11
78 16 ± 4 4:1 2% + + 0 + +
PL13 M 1948 2003 905 45
59 ±
13
38 14 ± 5 3:1 nd + + +1 + nd
II-3 M 1934 1991 701-1200 60
59 ±
13
88 14 ± 5 4:1 nd + + +1 + nd
*age norms based on reference (162)
** according to reference (153)
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Table 3 Comparison of characteristics of patients with familial and sporadic
thrombocythemia
Familial
thrombocythemia
(n= 23)
Sporadic essential
thrombocythemia
(n= 17)
P
value
Sex (male/ female) 8/15 8/9 0.43
Age at diagnosis, median (range) 35 (5- 81) 67 (16-84) 0.007
Time of follow up (months) 63 (0-242) 46 (0-180) 0.47
Platelets (x109/L); median (range) 890 (414-1400) 876 (452-1390) 0.78
Leukocytes (x109/L); median (range) 7.6 (5.3-10.7) 9.0 (5.3-10.7) 0.07
Number of patients with palpable splenomegaly 6 4 0.59
Rate and localization of clinical complications:
Total number of events 11 7 0.06
Total number of events (per 100 patient years) 8.3 22.6 0.06
Thrombotic events (per 100 patient years) 6.4 8.6 0.29
Venous thromboembolic events 0.6 3.2 0.20
Vasomotor symptoms/ functional
symptoms
1.3 1.1 0.45
Arteriovascular events 4.5 4.3 0.92
Hemorrhage (per 100 patient years) 0.6 11.8 0.009
Myelofibrosis  (per 100 patient years) 0 2.2 0.09
Transformation to acute leukemia 0 0
Causes of death:
Total numbers of deaths 4 1 -
Thrombocytosis-related deaths 2 0
Stroke 2 0 -
Hemorrhage 0 1 -
Unknown causes of death 2 0 -
When multiple events per patients occurred, every event was scored.
Vasomotor symptoms: only Raynaud’s phenomenon and erythromelalgia were scored. Cold tip feeling,
acral paresthesia
and headache were excluded. Limb paresthesia was included in arterial events
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Discussion 
We described a Polish family carrying the same splice donor mutation in intron 3 of the 
THPO gene as previously identified in a Dutch HT family.22 The mechanism by which 
this mutation increases TPO protein production is loss of translational inhibition from the 
5’-UTR of THPO mRNA.21,22 Although there is no obvious relatedness between members 
of the two families, it was conceivable that the mutation may have passed on from a 
common ancestor (founder effect). However, haplotype analysis for the two families 
showed differences in 3 genetic polymorphisms located near the mutation. Due to the 
very small physical distance between the mutation and the three SNPs (150, 507 and 
1’553 bp, respectively) a founder effect is highly unlikely. Therefore we conclude that 
the mutation in the two families arose de novo.  
 
The TPO serum concentrations in most affected family members were only slightly 
elevated or even normal, similar as in the Dutch family.22 A possible explanation is that 
the increase in platelet count and megakaryocyte mass lowers the serum concentration by 
binding TPO through its receptor MPL,33,34 reaching a new equilibrium at levels close to 
normal. Perhaps as a consequence of the increased internalization and degradation of the 
MPL-TPO complex,32,165 the MPL protein was decreased in platelets from most of the 
affected family members. The MPL mRNA levels in platelets were normal or even 
slightly elevated in affected individuals, indicating that the low MPL protein levels were 
not due to decease in mRNA expression. 
 
Histological appearances of bone marrow in HT showed some similarities to chronic 
myeloproliferative disorders. Marked increase and clustering of megakaryocytes, marrow 
hypercellularity and occasional mild reticulin fibrosis were seen.  However; in contrast to 
ET, the megakaryocytes of HT assumed very round compact shapes and were even more 
regular than megakaryocytes in normal controls.  These histological findings were 
confirmed by our objective planimetry-based analysis and may be potentially useful in 
resolving diagnostic dilemmas in thrombocythemias presenting with an unclear or 
missing familial history.  Interestingly, the bone marrow histology in an affected member 
of the Dutch family (II/3) we had an opportunity to review, was very similar, with 
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numerous and rather compact megakaryocytes showing tendency to clustering, mildly 
increased eosinophil granulocytes and minimal reticulin fibrosis. The megakaryocytic 
nuclei appeared slightly more complex, although not overtly atypical. The overall 
impression of bone marrow morphology corroborated close genotype-phenotype 
associations in this form of HT.  
 
A total of 23 affected family members with a median follow up of 5 years (range 0-20) 
were studied. The clinical consequences of increased TPO production and elevated 
platelet count were comparable with the clinical course of 17 patients reported 
previously.149 Venous thrombotic events, major vasomotor events and arterio vascular 
events occurred at a comparable rate as in ET patients. Hemorrhage occurred more 
frequently in ET patients. Main site of bleeding in these patients was the gastrointestinal 
tract, whereas no such event was reported in the familial thrombocytosis patients. As in 
ET patients, Minor vasomotor symptoms such as cold tip feeling and acral paresthesia 
respond well to aspirin in all affected patients. 
 
The clinical course in familial thrombocytosis patients is generally believed to be milder 
than in ET. However, in our patients we could not see a milder phenotype. This might in 
part be due to the small number of patients studied; these findings should be verified in a 
larger cohort of familial thrombocytosis patients. Nevertheless, to our knowledge, this is 
the largest cohort of patients reported so far. 
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Mutation analysis in families with hereditary thrombocythemia and 
identification of a founder effect for a MPL mutation 
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Abstract  
 
Background and Objectives.  Hereditary thrombocythemia (HT) is an autosomal 
dominant disorder characterized by sustained megakaryocytopoiesis with overproduction 
of platelets. Germ line mutations in HT families have been identified in the genes for 
thrombopoietin (THPO) and its receptor, MPL. Recently four families have been reported 
carrying the Ser505Asn mutation in MPL gene. Here we performed mutation analysis in 
11 HT families and haplotype analysis for families sharing the identical MPL mutation.  
Design and Methods. THPO and MPL gene were examined by genomic DNA 
sequencing. Haplotype analysis using microsatellites and single nucleotide 
polymorphisms (SNPs) were performed.  
Results. In 11 HT families we discovered one family carrying the Ser505Asn mutation in 
MPL gene whereas the other 10 families have normal THPO and MPL gene sequences. 
Haplotype analysis for a total of 6 HT families carrying the same MPL mutation suggests 
a found effect.    
Conclusions and interpretations.  The frequent occurrence of the MPL Ser505Asn 
mutation in HT families is due to a founder effect. Unknown genetic variations cause 
similar clinical phenotype in other HT families.  
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Introduction 
Hereditary thrombocythemia (HT) is an autosomal dominant disorder characterized by 
sustained megakaryocytopoiesis with overproduction of platelets, whose clinical features 
resemble sporadic essential thrombocythemia (ET). Thrombopoietin (TPO) and its 
receptor MPL regulate proliferation and maturation of megakaryocytes and thus platelet 
production. Germ-line mutations have been described in thrombopoietin gene (THPO) 
and MPL gene in HT families. All the five mutations identified in the THPO gene to date 
are located in the 5 prime untranslated region (5’-UTR) of the mRNA sequence, which 
contains upstream open reading frames (uORF) that inhibit the translation of THPO 
mRNA.21-27 The mutations remove the inhibitory uORFs and lead to increased translation 
of the THPO mRNA causing elevated TPO serum levels and overproduction of 
platelets.22,24 A missense mutation in the transmembrane domain of MPL has been 
identified in a Japanese family with HT.51 This G ? A transition changes a serine to an 
asparagine at amino acid position 505 (Ser505Asn). Mutant MPL protein is hyperactive 
and activates downstream signals to stimulate cell proliferation, which result in excessive 
platelet production. All the germ-line mutations in THPO and MPL gene have not been 
identified in sporadic patients with thrombocythemia,140 though mutations in a different 
location within juxtamembrane domain of MPL have been found in patients with chronic 
myeloproliferative disorders (MPD), in particular idiopathic myelofibrosis (IMF) and 
ET,54,55 One splice donor mutation in THPO gene was identified in a second HT family 
and arose de novo (Liu et al submitted). Recently four out of five families analyzed have 
shown carrying the Ser505Asn mutation in MPL gene,52 suggesting a relatively high 
frequency of this mutation in HT etiology. In some HT families THPO and MPL genes 
were excluded as the cause of thrombocytosis.143,144 In this study, we analyzed THPO and 
MPL gene in 11 HT families and discovered one family carrying the Ser505Asn mutation 
in MPL gene. The other 10 HT families have normal THPO and MPL gene sequences, 
indicating some unknown genetic lesion resulting in the similar phenotype. The frequent 
reoccurrence of this mutation in different HT families raise the question whether the 
mutation is originated from a single founder or multiple mutational events. We performed 
haplotype analysis for a total of 6 HT families carrying the Ser505Asn mutation in MPL 
gene. 
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Design and Methods 
 
Patients and clinical features 
The proposita, a 5-year-old came to our observation for asymptomatic thrombocytosis 
since birth. The patient was sent to our Institution for a suspect of essential 
thrombocythemia. However, clonogenic assays were essentially negative, and we 
investigated family history and blood cell counts, discovering that other 2 siblings in the 
same family over 3 generations had high platelet counts, i.e. the proposita’s father and 
grand-mother.  
 
THPO and MPL gene sequencing 
Genomic DNA was extracted from blood or buccal swab using a standard proteinase K 
(Promega, Madison, WI, USA)/phenol (Fluka Chemie AG, Buchs, Switzerland) 
extraction protocol.  Exons including intron/exon boundaries of the THPO and MPL gene 
were sequenced from PCR fragments, amplified from genomic DNA of one affected 
family member for each family. The primer sequences are shown in Supplementary Table 
1 and 2. The PCR conditions were 95ºC for 2 min, 94ºC for 30 sec, 60ºC for 30 sec and 
72ºC for 1 min for 35 cycles. Sequencing was performed on an Applied Biosystems 3130 
DNA sequencer (Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s protocols.  
 
Haplotype analysis 
To determine the founder effect, 4 informative microsatellite markers located in the 
vicinity of the MPL gene locus were used for haplotype analysis. Sequences of the 
primers are provided in Supplementary Table 3. The PCR products were analyzed using 
the Applied Biosystems 3130 genetic analyzer and the Genemapper software package 
version 3.5 (Applied Biosystems, Foster City, CA, USA). The haplotypes were 
determined based on the segregation within the pedigrees and the sizes of the PCR 
products of the co-segregating microsatellite markers were compared between affected 
members of the six families.  
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Results and Discussion 
The clinical features of 3 family members with thrombocytosis in our newly identified 
Italian family with the Ser505Asn mutation are summarized (Table 1). As compared to 
non-affected family members, platelets from affected siblings were significantly smaller 
(MPV of affected 8.7±0.4 fL, n=3; non-affected 11.0±0.7, n=5, p=0.0006) and had a 
narrower distribution of the population (PDW of affected: 10.6±0.8 versus 13.7±1.6, 
p<0.05). More interestingly, both MPV and PDW were higly-significantly inversely 
correlated to platelet counts within the affected and non-affected members. Thus, it 
appears that HT platelets, in spite of their increased number, are in fact smaller, which 
might compensate for the whole platelet circulating mass. Furthermore, platelet function 
was analyzed by the Platelet-Function-Analyzer (PFA)-100 methods which is a shear-
dependent test in whole blood. By this method the affected family members had 
consistently prolonged closure times in response to both collagen-ADP (CADP) and 
collagen-epinephrine (CEPI) cartridges.  
We did genomic DNA sequencing for the entire encoding sequences, the 5’-UTR, and the 
intron/exon boundaries of THPO and MPL gene for one affected family member from 11 
HT families (Figure 1). In one Italian family we identified a G?A transition in exon10 of 
MPL gene (Figure 2A). This mutation changes a serine into an asparagine in the amino 
acid sequence (Figure 2B). The mechanism by which this mutation increases platelet 
production is that the mutant MPL receptor is activated and stimulate downstream 
signaling pathway in a ligand independent fashion.51 The same mutation was found in 5 
additional HT families (Figure 3), and four of them have been reported recently.52  The 
frequent reoccurrence of this mutation in different families indicate that the mutation may 
have originated from a common ancestor (founder effect). We therefore performed 
haplotype analysis with microsatellite markers in the vicinity of the MPL mutation in 
affected members from the six families. A founder effect, i.e. descent of all families from 
a common allele, is expected to result in sharing of allelic sequence polymorphisms in the 
vicinity of the MPL mutation. We compared 3 microsatellite markers located between 42 
kb to 1290 kb from the MPL mutation, and all PCR products that represent the haplotype 
of the affected allele in the six families showed the idential sizes (Figure 4), suggesting 
that the mutation occurred from a single founder event.  
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Figure 1 Family pedigrees of the 9 HT families with normal THPO and MPL gene. 
Square represents male and circle female; solid symbol indicates affected, open 
unaffected, grey not studied and slash marks deceased. Unique patient numbers are 
shown below the symbols which correspond to the clinical data in Table 1. 
 
 
 
 
Table 1 Summary of clinical data of 3 members of the Italian family with
thrombocytosis.
UPN Sex Age
at
Dx
Platelets
150-450
x109/L
WBC
3.5-10.0
x109/L
RBC
4.2-6.3
x1012/L
Hemo-
globin
12-14 F
14-18 M
g/L
Spleno-
megaly
(last
follow
up)
PFA-100
assay
CEPI
(up to
195 sec)
PFA-100
assay
CADP
(up to
130 sec)
Hepato-
megaly
(last
follow
up)
Thrombocytosi
s-associated
symptoms
Important
co-
morbidity
RC02 F 64 926 7.2 4.20 12.9 No > 300 > 300 No None none
RC05 M 35 625 5.1 5.59 16.2 No 180 158 No None smoker
RC06 F 5 1092 7.7 4.75 13.4 No > 300 190 No No none
UPN, unique patient number; Dx, diagnosis; WBC, white blood cells; RBC, red blood cells
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Figure 2  The Italian family with Ser505Asn mutation. A) Pedigree of the Italian 
family. Square represents male and circle female; solid symbol indicates affected, open 
unaffected and grey not studied. Unique patient numbers are shown below the symbols. 
Platelet count number is shown below the unique patient number. Number in red is above 
the normal range. The genotype at the mutation point is indicated below the platelet 
counts. Noted that affected individual is heterozygous for the position, whereas 
unaffected are homozygous.  B) The sequencing chromatograms of the mutation region 
in MPL exon10 from an unaffected and an affected family member are shown. Noted that 
the G?A transition is a double peak. Bases and changed amino acid are indicated above 
the chromatograms.  
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Figure 3  Family pedigrees of the 5 HT families with Ser505Asn mutation in MPL 
gene. Square represents male and circle female; solid symbol indicates affected, open 
unaffected and slash marks deceased. Unique patient numbers that correspond to the ones 
in Table 3 are given below the symbols.  
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Figure 4  Haplotype analysis for the MPL locus in the five Italian HT families 
carrying the same Ser505Asn mutation. The chromosomal locus containing the MPL 
gene is shown. Black box represents the MPL gene and open boxes genes close to it: 
MPL, myeloproliferative leukemia virus oncogene; TMEM125, transmembrane protein 
125;  TIE, tyrosine kinase with immunoglobulin-like and EGF-like domains 1; CDC20, 
cell division cycle 20 homolog (S. cerevisiae); ELOVL1, enlongation of very long chain 
fatty acids (FEN/E102, SUR4/E103, yeast)-like 1; MED8, mediator of RNA polymerase 
II transcription subunit 8 homolog (S. cerevisiae); HIY, hydroxypyruvate isomerase 
homolog (E. coli). The distances of microsatellite markers to the location of mutation are 
shown above the locus.  Names of markers are shown below the locus, and numbers 
below the markers indicate the sizes in nucleotides of the PCR products of the co-
segregating mutated alleles in the five families. Note that all the allele sizes are identical 
in the six families.  
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RESULTS II: 
 
 
 
Genetic studies of a hereditary thrombocythemia family with normal 
thrombopoietin and MPL gene 
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Abstract  
 
Background and Objectives.  Hereditary thrombocythemia (HT) is an autosomal 
dominant disorder with clinical features resembling sporadic essential thrombocythemia 
(ET). Although germ line mutations causing HT have been identified in the genes for 
thrombopoietin (THPO) and its receptor, MPL, genetic lesions for many HT families 
remain unknown. Here we studied a HT pedigree with 10 affected family members. 
Design and Methods. Linkage analysis was performed using microsatellites and SNP 
chip arrays. Candidate genes were selected for genomic DNA sequencing. A candidate 
mutation was cloned into retroviral vectors to infect cell lines and mouse bone marrow 
cells for transplantation.  Cell proliferation rate was tested in cell lines transfected with 
candidate gene. Peripheral blood counts were determined in transplanted mice. 
Results. We identified two genetic regions that co-segregated with thrombocytosis within 
the pedigree. Candidate gene sequencing revealed one novel polymorphism in the 
gelsolin gene, which changed a glycine into a cysteine in the protein sequence. Cell lines 
transfected with the candidate mutant gelsolin did not show any proliferation advantage 
over the wild type. Blood counts were normal in mice transplanted with bone marrow 
expressing the candidate mutant gelsolin. The other 33 candidate genes in the co-
segregating region were also sequenced but no variant was found.   
Conclusions and interpretations. Genome-wide linkage analysis for this HT family 
leads to the identification of two genetic regions. Sequencing candidate genes in these 
two regions is under way. One candidate mutation in gelsolin needs futher functional 
studies to validate it as disease causing mutation.   
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Introduction 
 
Hereditary thrombocythemia (HT), also known as familial thrombocytosis or familial 
essential thrombocythemia is characterized by sustained proliferation of megakaryocytes 
and overproduction of platelets, which is often clinically indistinguishable from the 
sporadic essential thrombocythemia (ET). HT is inherited as an autosomal dominant trait 
with a nearly hundred percent penetrance. The pathogenesis for some HT families has 
been elucidated with the discovery of germ-line mutations in genes encoding the primary 
regulators for platelet production thrombopoietin (TPO) and its receptor, MPL. To date, 
five different germ-line mutations in the thrombopoietin (THPO) gene have been 
identified and all of them alter the 5 prime untranslated region (5’-UTR) of the THPO 
mRNA, which contains upstream open reading frames (uORF) that inhibit the translation 
of THPO mRNA.21-27 The mutations remove the inhibitory uORFs and lead to increased 
translation of the THPO mRNA causing elevated TPO serum levels and overproduction 
of platelets.22,24 A missense mutation in the transmembrane domain of MPL has been 
identified in several HT familes.51,52 This mutation changes a serine to an asparagine in 
the MPL protein sequence. The mutant MPL protein is hyperactive and results in 
excessive platelet production. Recently, mutations in the juxtamembrane domain of MPL 
have been found in patients with the chronic myeloproliferative disorders (MPD), in 
particular idiopathic myelofibrosis (IMF) and ET,54,55 but THPO mutations have not been 
detected in patients with sporadic MPD.140 In some HT families, both THPO and MPL 
genes can be excluded as the cause of thrombocytosis and thus, other as yet unknown 
genes must be involved in causing an identical phenotype.143,144 Here we performed 
genetic study on a previously described HT family,166 in which THPO and MPL genes 
were excluded as the disease-causing genes,144 to search for novel genetic lesion causing 
the thrombocytosis.  
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Design and methods 
 
Patients and clinical features 
The clinical features of this family have been described previously.166 Briefly, the 
propositus had a persistent elevation of platelet counts in the range of 1000 x 109 per liter, 
splenomegaly, a normal hemoglobin and white blood cell count. Her mother and her 
maternal aunt, and her two sons were later found to display high platelet counts.  In the 
propositus, her mother and her older son platelet aggregation tests were abnormal 
including disaggregation to ADP, no response to epinephrine, delayed aggregation to 
collagen, and delayed submaximal response to arachidonic acid. Bleeding time was 
normal in the propositus, whereas her mother has a prolonged bleeding time. For our 
study, more family members were recruited. In total, 10 affected and 11 unaffected 
family members participated in the genetic study.  
 
Blood cells separation, DNA and RNA extraction 
Blood cells were separated by standard protocols using Histopaque (Sigma, St. Louis, 
MO, USA) gradient centrifugation. Granulocytes and peripheral blood mononuclear cells 
(PBMC) were collected respectively. Platelets were collected using the Sepharose 
(Amersham Pharmacia Biotech AB, Uppsala, Sweden) gel filtration method.155 DNA was 
extracted using a standard proteinase K (Promega, Madison, WI, USA)/phenol (Fluka 
Chemie AG, Buchs, Switzerland) extraction protocol. RNA isolation was carried out 
using the TRIfast reagent (peqLab Biotechnology GmbH, Erlangen, Germany).  
 
Genotyping 
Linkage mapping set v2.5-MD10 (Applied Biosystems, Foster City, CA, USA) was used 
for genome-wide analysis. Genomic DNAs were PCR amplified and analyzed with an 
ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s protocol. The PCR program was at 94ºC for 15 sec, 55ºC for 15 sec, 72ºC 
for 30 sec for 10 cycles, 89ºC for 15 sec, 55º for 15 sec and 72ºC for 30 sec for 20 cycles. 
The Affymetrix GeneChip Human Mapping 50K Xba 240 was used to genotype single 
nucleotide polymorphisms (SNPs) in genomic DNA of 12 family members according to 
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the Affymetrix GeneChip Mapping Assay Manual (Affymetrix Inc., Santa Clara, CA, 
USA)  
 
Linkage analysis 
Genotypes from microsatelite mapping were scored using the Genemapper software 
package version 3.5 (Applied Biosystems, Foster City, CA, USA) and linkage analysis 
was carried out by FASTLINK software package version 4.1p. The SNP calls were 
generated by GeneChip DNA Analysis Software. dCHIP version 2005 was used to 
perform parametric linkage analysis.167 An autosomal dominant inheritance model with a 
100% penetrance was used for both analyses.  
 
Genomic DNA sequencing 
The entire coding region including intron/exon boundaries of candidate genes was 
sequenced from PCR fragments amplified from genomic DNA of one affected family 
member, EY01. The primer sequences are available upon request. The PCR conditions 
were 95ºC for 2 min, 94ºC for 30 sec, 60ºC for 30 sec and 72ºC for 1 min for 35 cycles. 
Sequencing was performed on an Applied Biosystems 3700 DNA sequencer (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s protocols.  
 
cDNA synthesis, RT-PCR and Quantitative RT-PCR 
Total RNA (2 μg) was reverse transcribed to generate cDNA using Superscript II reverse 
transcriptase (Life Technologies). Real-time PCR primers for ribosomal protein L19 
(RPL19) and gelsolin were designed across exon-intron junctions. In addition, primers for 
gelsolin were designed specific for human sequence to distinguish the expression of 
human gelsolin in mouse bone marrow. The primer sequences are available upon request. 
The ?CT values were derived by subtracting the threshold cycle (CT) values for target 
genes from the CT value for RPL19, which served as an internal control.
158 Relative 
expression level for each reaction was calculated as 2-?CT. Folds were calculated with one 
calibrator set as 1. All reactions were run in duplicates using the ABI 7000 Sequence 
Detection System  (Applied Biosystems, Foster City, CA, USA).  
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Western blotting 
Protein lysate was denatured at 95°C for 2 minutes and separated by 10% sodium 
dodecyl sulfate-plyacryamide gel electrophoresis (SDS-PAGE). The gel was transferred 
electrophoretically onto 0.45-μM nitrocellulose membrane (Whatman GmbH, Dassel, 
Germany).168 The membrane was blocked with 5% nonfat milk in 1 x PBS with 1% 
Tween-20 for 2 hours at room temperature and incubated overnight at 4°C with diluted 
primary antibody and then probed with a mouse monoclonal antibody (BD Biosciences, 
San Jose, CA, USA) or a goat polyclonal antibody (Santa Cruz Biotechnology, CA, 
USA). The membranes were re-probed using a monoclonal antibody against human 
CD61 (BD Biosciences, San Jose, CA, USA) serving as a loading control.  
 
DNA construct 
A human gelsolin cDNA clone in pOTB7 vector was purchased from RZPD (Germany). 
The full length gelsolin cDNA was PCR amplified using primers with XhoI and EcoRI 
restriction enzyme cutting sites and then cloned in pSP72 vector (Promega).   The 
candidate mutant gelsolin cDNA fragment was amplified by RT-PCR using platelet RNA 
isolated from one affected family member (EY03) and cloned into the pCR 2.1-TOPO 
vector (Invitrogen). The candidate mutant fragment was cut out and inserted into the 
PSP72 vector containing gelsolin cDNA. The wild type and candidate mutant gelsolin 
were finally cloned into the retroviral vector pMSCVpuro and MSCV2.2IRESGFP 
encoding green fluorescent protein (kindly provided by Dr. J. Cools, Flanders 
Interuniversity Institute for Biotechnology, Leuven, Belgium). The gelsolin cDNA in the 
resulting expression construct was verified by sequencing.  
 
Cell proliferation assay 
Stably transfected BaF3 cells, 32D cells and UT7 cells were selected with puromycin (2.5 
μg/ml for BaF3 and 32D cells and 0.625 μg/ml for UT7 cells). The proliferation of the 
cells grown for 3 days in presence of cytokines at different concentrations was assessed 
using the Cell proliferation kit II XTT (Roche Molecular Biochemicals).  
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Retrovirus production and Bone marrow transplantation in mice 
Equal amounts of retroviral vector with gelsolin and packaging plasmids (Ecopak) were 
incubated with FuGene 6 reagent (Roche Applied Science) for 10 minutes, and then 
added to the human embryonic kidney-cell line, 293T. The supernatants were harvested 
48 and 72 hours later and used to transfect murine bone marrow cells. BALB/c donor 
mice (6-10 weeks old) were injected with 5-fluorouracil at 150 mg per kg of body weight 
5 days before harvesting bone marrow from femurs and tibias. Cells were cultured for 24 
hours in transplantation medium (RPMI-1640 medium, 10% fetal-calf serum, 6 ng/ml of 
murine interleukin-3, 10 ng/ml of human interleukin-6, and 10 ng/ml of murine stem-cell 
factor) and then transfected with retrovirus supernatant. Briefly, 4 x 106 bone marrow 
cells were centrifuged at 2500 rpm for 90 minutes in the presence of 1 ml of retroviral 
supernatant and 2 μl of Polybrene Infection Transfection Reagent (American 
Bioanalytical).  Cells were infected for a second time on the day after and subsequently 
resuspended in Hank's balanced salt solution (Gibco) and then injected into lethally 
irradiated BALB/c mice. Peripheral-blood counts were evaluated for each recipient 4 
weeks after transplantation. 
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Results 
Genome-wide linkage analysis for 21 family members using microsatellite markers 
revealed one region on chromosome 9q that co-segregated with the thrombocytosis with 
the highest logarithm of odds (LOD) score of 3.9 at theta = 0 (Figure1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Segregation of microsatellite markers on chromosome 9. Filled black 
symbols, affected individuals; open symbols, normal individuals; filled grey symbols, not 
studied; crossed symbols, deceased. Unique patient numbers are placed below the 
symbols. Haplotypes for nine polymorphic microsatellite markers from D9S1856 through 
D9S123 are shown with numbers defined by different sizes of PCR fragments. The 
unique haplotype linked with the disease is boxed. 
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The 11 Mb region contains 106 genes, including a core region with LOD score higher 
than 3 (17 genes) and two flanking regions at each side with LOD score between –2 and 
3, which could not be exclude statistically. SNP chip arrays for 13 family members 
confirmed the genetic region on chromosome 9q and identified an additional region on 
chromosome 20 (Figure 2). The highest LOD score from SNP chips data of 13 family 
members was 2.68. The core region on chromosome 9q from SNP arrays was slightly 
larger than the one from microsatellite mapping containing 29 genes (Table 1). The 
candidate genes on chromosome 20q are summarized in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2   Parametric linkage analysis of 50K SNP array Xba 240 for 13 family 
members. A) The whole genome Lod score curve was plotted on the right side with a 
threshold from –2 to 3, Lod score of 2 is indicated by a red line. Genotypes of each 
family member are shown on the left side with different colors, red represents AA, blue 
BB, and yellow AB. B) The LOD score curve of the segregating region on chromosome 
9q and chromosome 20q. The region on chromosome 9q is consistent with the one from 
microsatellite markers with the highest LOD score of 2.68.  
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Table 1 Overview of genes in the region of chromosome 9q 
Gene Symbols   Gene Full Names 
TRIM32   tripartite motif-containing 32  
TLR4   toll-like receptor 4  
LOC340477  hypothetical LOC340477  
LOC389787  similar to Translationally controlled tumor protein (TCTP) (p23) (Histamine-    
          releasing factor) (HRF)  
LOC442434  similar to beta-tubulin 4Q  
DBC1   deleted in bladder cancer 1  
CDK5RAP2  CDK5 regulatory subunit associated protein 2 
EGFL5   EGF-like-domain, multiple 5  
LOC392387  similar to Adenosylhomocysteinase (S-adenosyl-L-homocysteine hydrolase)  
(AdoHcyase)  
FBXW2   F-box and WD-40 domain protein 2  
LOC402377 similar to beta-1,3-N-acetylglucosaminyltransferase bGnT-5; beta 1,3 N-
acetyglucosaminyltransferase Lc3       
         synthase  
PSMD5   proteasome (prosome, macropain) 26S subunit, non-ATPase, 5  
PHF19   PHD finger protein 19  
TRAF1   TNF receptor-associated factor 1  
C5   complement component 5  
CEP1   centrosomal protein 1  
RAB14   RAB14, member RAS oncogene family  
GSN   gelsolin (amyloidosis, Finnish type)  
LOC441464  LOC441464  
LOC441465  hypothetical gene supported by AK130710  
STOM   stomatin  
GGTA1   glycoprotein, alpha-galactosyltransferase 1 
LOC441466  similar to HMG-1  
DAB2IP   DAB2 interacting protein  
C9orf20   chromosome 9 open reading frame 20  
C9orf148  chromosome 9 open reading frame 148  
NDUFA8  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa 
C9orf18   chromosome 9 open reading frame 18 
LHX6   LIM homeobox 6 
 
Total number of genes   29 
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Table 2 Overview of genes in the region of chromosome 20q 
Gene Symbols   Gene Full Names 
TMEPAI  transmembrane, prostate androgen induced RNA 
C20orf85  chromosome 20 open reading frame 85 
C20orf86  chromosome 20 open reading frame 86 
PPP4R1L  protein phosphatase 4, regulatory subunit 1-like 
RAB22A  RAB22A, member RAS oncogene family 
VAPB   VAMP (vesicle-associated membrane protein)-associated protein B and C 
APCDD1L  adenomatosis polyposis coli down-regulated 1-like 
LOC149773  hypothetical protein LOC149773 
MGC4294  hypothetical protein MGC4294 
STX16   syntaxin 16 
NPEPL1  aminopeptidase-like 1 
LOC391258  hypothetical LOC391258 
SANG   GNAS1 antisense 
GNAS   GNAS complex locus 
TH1L   TH1-like (Drosophila) 
CTSZ   cathepsin Z 
LOC729181  hypothetical protein LOC729181 
TUBB1   tubulin, beta 1 
ATP5E   ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit 
C20orf45  chromosome 20 open reading frame 45 
MRPS16P  mitochondrial ribosomal protein S16 pseudogene 
C20orf174  chromosome 20 open reading frame 174 
EDN3   endothelin 3 
LOC645605  similar to Protein FAM38A 
PHACTR3  phosphatase and actin regulator 3 
 
Total number of genes   25 
 
We did genomic DNA exon sequencing for all the 29 candidate genes on chromosome 9q 
and 5 candidate genes on chromosome 20. One novel polymorphism in exon 6 of 
thegelsolin gene was found in all affected family members (Figure 3A). This G?T 
transversion changed a glycine into a cysteine in the second of its six gelsolin-like 
domains. Expression levels of gelsolin mRNA in platelets were determined in 3 affected 
and 2 unaffected family members and did not show significant differences (Figure 3B). 
Gelsolin protein levels were also measured in platelets protein lysates and no variation 
was observed between the affected and unaffected family members (Figure 3C). 
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Figure 3  The Candidate mutation in the gelsolin gene. A) Sequencing chromatograms 
of the polymorphism in gelsolin which are cloned in expression vectors. In all affected 
family members there is a G?T transversion causing a change of glycine to cysteine. B) 
Gelsolin mRAN levels in platelet cDNA in 2 unaffected and 3 affected family members 
available.  Relative mRNA level were calculated from ?CT values and plotted in 
logarithmic scale. The horizontal line indicates the mean for each group. C) Western 
blotting of gelsolin in platelet protein of unaffected and affected family members. CD61 
is reprobed to the membrane as a loading control. 
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The candidate mutant and wild type human gelsolin gene were cloned into retroviral 
expression vectors to generate stably transfected cell lines. In the mouse interleukin-3–
dependent cell line BaF3, the over expression of candidate mutant gelsolin did not show 
any proliferation advantage compared with the wild type gelsolin or empty vector (Figure 
4). Similar results were observed in UT7 cells and 32D cells (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  Cell proliferation XTT assay. A) Proliferation of BaF3 cells transfected with 
the gelsolin candidate mutant, wild-type, or the empty vector in the absence of 
interleukin-3 (concentration of 0) and the presence of increasing concentrations of 
interleukin-3, as determined by the tetrazolium salt (XTT) assay. The mean (±SD) of 
triplicate results is shown. Increased optical density (OD) of the XTT dye corresponds to 
increased numbers of cells. B) Over-expression of gelsolin protein. Western blotting was 
performed using an antibody against human gelsolin in cell lysates. Over-expression of 
gelsolin was detected in cells transfected with candidate mutant, the wild type, but not in 
cells with the empty vector.  
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Retroviral vectors expressing mutant and wild type human gelsolin were used to infect 
mouse bone marrow cells and then transplant these cells into lethally irradiated mice. 
Transplanted mice were physically normal. Peripheral blood counts at 4 weeks, 10 weeks 
and 20 weeks after bone marrow transplantation did not show variations in platelet 
numbers (Figure 5A), hemoglobin concentrations, or white blood cells numbers (data not 
shown). The efficiency of transplantation in mouse bone marrow cells determined by 
flow cytometry based on the green fluorescent protein (GFP) was 13.7% in the wild type 
gelsolin and 28.5% in the candidate mutant gelsolin (Figure 5B). The mRNA levels of 
human gelsolin were detected in sorted cells by real-time PCR using primers specific for 
the human gelsolin sequence. Up to 100 folds of increase in human gelsolin mRNA in 
FACS-sorted GFP positive mouse bone marrow cells compared to GFP negative cells 
was detected (Figure 5C). The over expression of human gelsolin protein were detected 
in the GFP positive cells. Though the antibody was against both mouse and human 
gelsolin, mouse gelsolin protein was undetectable in the GFP negative cells (Figure 5D).  
In total, 30 HT families, 172 sporadic MPD patients as well as 102 normal controls were 
screened for the polymorphism in gelsolin and none of them showed the same variation.  
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Figure 5   Recipient mice after transplantation with bone marrow cells transduced 
with gelsolin. A) The platelet counts of recipient mice 4 weeks, 10 weeks and 20 weeks 
after bone marrow transplantation are shown with boxes that represent the interquartile 
range that contains 50% of the values, the horizontal line in the box marks the median 
and bars indicate the range of values. B) FACS based on GFP in mice bone marrow cells 
transplanted with candidate mutant or wild type gelsolin. C) The mRNA levels of human 
gelsolin in sorted mouse bone marrow cells are shown. The mRNA levels of gelsolin in 
the platelets from one affected family member EY01 was set as 1 fold. D) Western 
blotting for gelsolin protein in sorted mice bone marrow cells. CD61 was used as a 
loading control.  
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Discussion and perspectives 
 
The disease-causing gene mutations are unknown in many HT families.139 Here we 
performed genome-wide linkage analysis for a HT family with normal TPO and MPL 
using two methods: microsatellite marker mapping and SNP chip array mapping. One co-
segregating region on chromosome 9q containing 29 candidate genes was revealed by 
both methods with the highest LOD score of 3.9.  By sequencing all the candidate genes 
we identified one novel polymorphism in the gelsolin gene. Gelsolin is an actin-binding 
protein abundant in platelets. Gelsolin-null mice have normal embryonic development 
and longevity but decreased platelet shape changes and prolonged bleeding time.169 A 
point mutation at the nucleotide position 654 of the gelsolin cDNA causes familial 
amyloidosis of the Finnish type (FAF). This mutation causes an amino acid substitution 
of aspartic acid at residue 187 by either asparagine or tyrosine.170-172 Though there is no 
evidence showing gelsolin involved in thrombocytosis, it has been shown that gelsolin 
has multiple biological properties in addition to cytoskeletal actin modulation. Gelsolin is 
cleaved by caspase-3 and may operate as an executor of apoptosis.173 Additionally, it has 
been long regarded as tumor suppressor in breast cancer and other carcinomas because of 
its down-regulation during tumor progression.174 Gelsolin appears to act down-stream of 
Ras and phosphoinositides to promote motility and invasive potential of transformed cell 
lines.175 
Over-expression of candidate mutant gelsolin in mouse and human cell lines did not 
show any proliferation advantages compared to the wild type gelsolin or to the empty 
vector, which suggests that gelsolin might not be involved in the pathways regulation cell 
proliferation. Bone marrow transplantation of candidate mutant gelsolin did not generate 
thrombocytosis or any other obvious phenotype in mice. The data so far do not support 
gelsolin as the disease-causing gene in this family though inheriance of the 
polymorphism in this gene is compatible with such a hypothesis. The candidate mutation 
was not detected in other HT families, sporadic MPD patients and normal controls, 
indicating that this variation is rare. A second allele in a HT family would be a strong 
indicator that mutant gelsolin is the disease causing gene.   
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Several other functional studies for the candidate mutant gelsolin are planned. First is to 
study the process of platelet releasing in megakaryocytes cultured in vitro. Since our data 
showed that over expression of gelsolin did not increase the proliferation rate of cells, the 
high platelet counts might be due to a defect in the platelet releasing process, which 
remains poorly understood to date. Platelet formation and releasing from megakaryocytes 
requires complicated changes in the cytoskeletal organization including microtubule 
enlongation and actin assembling.66,176 Actin is the most abundant protein in platelets. 
Gelsolin, as a member of the actin-binding protein family, is thought to function in 
capping, severing, nucleating or bundling actin filaments. Expression of gelsolin protein 
was detected in platelets in our study and many other studies. Besides, abnormal platelets 
functions were reported in affected family members. Therefore it is of interest to see if 
the candidate mutant gelsolin plays a role in the over production of platelets in this 
family. A second approach is to perform bone marrow transplantation using mouse 
gelsolin. Human and mouse gelsolin share 95% similarity at the amino acid sequences. 
Though transplanted human gelsolin failed to produce any phenotype in mice, the reason 
could be that human gelsolin is unable to interact with mouse signal molecules or too low 
infection rate.  
Although gelsolin is considered as a top candidate in this family, it is possible that 
another gene might carry the disease-causing mutation. Sequencing of genes in the 
segregating region on chromosome 9q has not been fully completed due to some PCR-
related technical problems. Additionally, only 5 candidate genes in the region on 
chromosome 20q identified by SNP chips array were sequenced. There are still 20 genes 
in this area that remain uncharacterized for this study. Searching for disease-causing gene 
in this family still needs complete sequencing for all genes.  
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RESULTS III: 
 
 
Genetic analysis of a family with congenital secondary polycythemia 
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Abstract 
Background and Objectives. Polycythemia is a condition with an increased red blood 
cell mass. Erythropoietin (EPO) receptor gene and VHL gene mutations have been 
described in families with primary familial and congenital polycythemia and Chuvash 
polycythemia, respectively. Here we performed genetic analysis for a family with 
congenital secondary polycythemia.   
Design and Methods. Linkage analysis was performed using microsatellite markers and 
Affymetrix GeneChips. Top candidate genes were studied in detail. EPO gene expression 
was measured under normoxia and hypoxia conditions.  
Results. We identified 5 genetic regions containing 325 genes that co-segregated with 
erythrocytosis in the pedigree. Top candidate genes in the regions and genes involved in 
erythropoiesis and oxygen sensing pathway were sequenced but no mutation was found. 
Cells from the Burst forming unit-Erythroid colonies showed higher EPO mRNA levels 
in hypoxia condition in 3 out of 4 affected family members.  
Conclusions and interpretations. Genetic linkage study revealed genetic regions and 
possible genes linked with the polycythemia, however genetic lesions causing the 
polycythemia and associated phenotypes in this family remain unknown.  
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Introduction 
 
Polycythemia is a condition with a net increased red blood cell mass. It can be classified 
into primary and secondary polycythemia based on its pathogenesis. In primary cases, the 
overproduction of red blood cells is due to an innate defect to the erythroid progenitor 
cells resulting in abnormal response to circulating hormones, mostly erythropoietin 
(EPO). In contrast, secondary polycythemias are caused by external factors, which act on 
normal erythroid progenitors.  
Both primary and secondary polycythemias may arise as acquired or congenital. 
Congenital polycythemias are primary when inherited mutations lead to increased 
responsiveness of red blood cell precursors to EPO. Primary familial and congenital 
polycythemia (PFCP), an autosomal dominant familial disorder, is a well-studied 
example. Numerous mutations in the endoplasmic domain of the EPO receptor gene 
(EPOR) have been described in pedigrees with PFCP, which all result in truncations of 
the EPOR and thus loss of the negative regulatory domain of the protein.139 The retained 
positive domain is reinforced and associated with JAK2/STAT5 proteins to stimulate 
erythropoiesis.177 None of these mutations were found in sporadic patients,141,142 and 
EPOR was excluded as the disease-causing gene in some PFCP families.145 
Chuvash polycythemia, on the contrary, is secondary to a defect in the oxygen sensing 
pathway due to germline mutations in the von Hippel-Lindau tumor suppressor (VHL) 
gene. As the only known endemic congenital polycythemia, Chuvash polycythemia is an 
autosomal recessive disorder caused by a homozygous mutation in VHL gene.178 The 
main regulator of oxygen homeostasis is hypoxia-inducible factor (HIF1), which is a 
transcription factor regulating many downstream target genes such as EPO, vascular 
endothelial growth factor (VEGF), transferring (TF), transferring receptor (TFRC), etc.179 
HIF1 is a heterodimer of two subunits, HIF1? and HIF1?.180 Only HIF1? can be 
regulated by oxygen level. At normoxia HIF1? level is maintained low through 
ubiquitin-mediated degradation of the protein.181 Hypoxia condition reduces the 
degradation rate of HIF1? protein, thereby increasing the cellular protein level of HIF1? 
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and stimulating transcription of target genes. 114 The polyubiquitination of HIF1? requires 
VHL protein and proline hydroxylase (PHD) activity.118,119 A missense mutation in the 
VHL gene in Chuvash polycythemia impairs the interaction between VHL and HIF1? 
and therefore reduces the ubiquitination and degradation of HIF1? protein.  The 
excessive HIF1? protein induces the transcription of downstream genes including 
EPO.137 A large portion of congenital polycythemia is due to altered oxygen sensing, but 
does not carry any VHL gene mutation.  Genes linked to oxygen sensing pathway 
became top candidates for mutation screening in these polycythemias. A missense 
mutation in PHD2 gene has been described as the cause for an autosomal dominant 
inherited polycythemia in a family.138 
In this study, we analyzed a family with congenital secondary polycythemia. Although 
similar to Chuvash polycythemia to some extent such as the autosomal recessive 
inheritance pattern and high serum EPO levels, this family has some unique clinical and 
laboratory features. Five out of 6 siblings are affected with unaffected parents and 3 
unaffected persons in the third generation. The number of affected individuals is against 
the odds as a recessive trait, possibly surggesting undiscovered consanguinity or 
incomplete penetrance in this family. In addition to high red blood cell counts, 3 affect 
males also have low platelet numbers. Genome-wide linkage mapping was performed and 
5 segregating regions were identified. Interestingly, the VHL gene is located in one of the 
regions. Sequencing and expression analysis did not reveal any variation in the VHL 
gene. Several other candidate genes in the mapped regions as well as genes associated 
with oxygen sensing and erythropoiesis were sequenced but none of them show 
polymorphisms linked to the polycythemia phenotype in this family. Burst forming units-
Eryroid (BFU-E) cultures in hypoxia condition showed high levels of EPO mRNA in 3 
out of 4 affected family members, suggesting a potential unknown defect in the oxygen 
sensing pathway. Genetic lesions causing the polycythemia and associated phenotypes in 
this family remain to be clarified.  
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Design and methods 
Patients, clinical and laboratory features 
Five of 6 siblings (2 woman, twins, and 3 men) display elevated Hemoglobin levels since 
early years of life, ranging between 20,7-24 g/dL. Hematocrit range is 61-73,4 %. No 
additional affected relatives were found. Blood cell mass was high (65 mL/Kg) in the 
propositus (DL02), in whom organic lesions have been ruled out. All 5 affected 
individuals had normal leucocyte counts, and 3 male patients displayed decreased platelet 
counts, inversely proportional to Hemoglobin levels. All patients but one had elevated 
serum EPO levels (range ELISA: 9-68 U/L); all have normal pO2, Hemoglobin 
electrophoresis, 2,3-diphosphoglycerate (2,3-DPG) levels and p50. BFU-E cultures 
showed a normal pattern of Epo-dependent growth. 3 male patients had elevated serum 
EPO levels 24 hours after phlebotomies (5-70 mU/mL over basal values). 
 
Blood cells separation, DNA and RNA extraction 
Blood cells were separated by standard protocols using Histopaque (Sigma, St. Louis, 
MO, USA) gradient centrifugation. Granulocytes and peripheral blood mononuclear cells 
(PBMC) were collected respectively. Platelets were collected using the Sepharose 
(Amersham Pharmacia Biotech AB, Uppsala, Sweden) gel filtration method.155 DNA was 
extracted using a standard proteinase K (Promega, Madison, WI, USA)/phenol (Fluka 
Chemie AG, Buchs, Switzerland) extraction protocol. RNA isolation was carried out 
using the TRIfast reagent (peqLab Biotechnology GmbH, Erlangen, Germany).  
 
Genotyping 
The linkage mapping set v2.5-MD10 (Applied Biosystems, Foster City, CA, USA) was 
used for genome-wide analysis. Genomic DNAs were PCR amplified and analyzed with 
an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s protocol. The PCR program was at 94ºC for 15 sec, 55ºC for 15 sec, 
72ºC for 30 sec for 10 cycles, 89ºC for 15 sec, 55º for 15 sec and 72ºC for 30 sec for 20 
cycles. The Affymetrix GeneChip Human Mapping 50K Xba 240 was used to genotype 
single nucleotide polymorphisms (SNPs) in genomic DNA of 12 family members 
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according to the Affymetrix GeneChip Mapping Assay Manual (Affymetrix Inc., Santa 
Clara, CA, USA)  
 
Linkage analysis 
Genotypes from microsatelite mapping were scored using the Genemapper software 
package version 3.5 (Applied Biosystems, Foster City, CA, USA) and linkage analysis 
was carried out by FASTLINK software package version 4.1p. The SNP calls were 
generated by GeneChip DNA Analysis Software. dCHIP version 2005 was used to 
perform parametric linkage analysis.167 An autosomal recessive inheritance model with a 
100% penetrance was assumed for both analyses.  
 
Genomic DNA sequencing 
The entire coding region including intron/exon boundaries of candidate genes was 
sequenced after PCR amplification of genomic DNA from one affected family member, 
DL04. The primer sequences are available upon request. The PCR conditions were 95ºC 
for 2 min, 94ºC for 30 sec, 60ºC for 30 sec and 72ºC for 1 min for 35 cycles. Sequencing 
was performed on an Applied Biosystems 3700 DNA sequencer (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s protocols.  
 
BFU-E culture in hypoxia condition 
PBMCs from family members as well as healthy volunteers were cultured in 35-mm Petri 
dishes using semisolid medium (Methocult H4431; Stem Cell Technologies Inc, 
Vancouver, BC, Canada) in a hypoxia chamber with 1% oxygen and 5% CO2 at 37°C for 
14 days. BFU-E colonies were then harvest and checked for EPO expression.   
 
cDNA synthesis, RT-PCR and Quantitative RT-PCR 
Total RNA (2 μg) was reverse transcribed to generate cDNA using Superscript II reverse 
transcriptase (Life Technologies). cDNAs were PCR amplified to detect VHL and EPO 
expression at the condition described above. The quantitative real-time PCR primers for 
ribosomal protein L19 (RPL19), VHL and EPO were designed across exon-exon 
junctions. The primer sequences are available upon request. ?CT values were derived by 
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subtracting the threshold cycle (CT) values for target genes from the CT value for RPL19, 
which served as an internal control.158 Relative expression level for each reaction was 
calculated as 2-?CT. A non-affected family member DL01 was chosen as a calibrator for 
calculating the ??CT values.160,182 All reactions were run in duplicates using the ABI 
7000 Sequence Detection System  (Applied Biosystems, Foster City, CA, USA).  
 
Western blotting 
Protein lysate was denatured at 95°C for 2 minutes and separated by 10% sodium 
dodecyl sulfate-olyacryamide gel electrophoresis (SDS-PAGE). The gel was transferred 
electrophoretically onto 0.45-uM nitrocellulose membrane (Whatman GmbH, Dassel, 
Germany).168 The membrane was blocked with 5% nonfat milk in 1 x PBS with 1% 
Tween-20 for 2 hours at room temperature and incubated overnight at 4°C with diluted 
primary antibody. The primary rabbit anti-VHL polyclonal antibody was kindly provided 
by Professor Willy Krek (Swiss Federal Institute of Technology, Zurich). The 
membranes were re-probed using a monoclonal antibody against human CD61 (BD 
Biosciences, San Jose, CA, USA) serving as a loading control.  
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Results 
 
The clinical features of 5 family members with erythrocytosis are summarized (Table 1). 
Erythrocytosis in all of the patients was detected in their childhood. Four patients have 
hyperviscosity symptoms. Most of these symptoms are manageable using phlebotomy. 
Genome-wide linkage analysis for 12 family members using microsatellite markers 
revealed 2 genetic regions co-segregating with the erythrocytosis in the family. The 
highest LOD score for the informative markers is 2.53. One region is on chromosome 3, 
in which the VHL gene is localized. Fine mapping for this region with additional 
microsatellite markers in close vicinity reduced the size of this region to 21 Mega bases 
(Mb) containing 180 genes (Figure 1).  
 
Table 1 Clinical characteristics of 5 family members with polycythemia. 
 
UPN Sex Date 
of 
Birth 
Date of 
diagnosis 
Date 
of last 
follow 
up 
Hemo-
globin 
12-14 F 
14-18 M 
g/L 
 
Hematocrit
(%) 
Platelets 
150-450 
x109/L 
WBC 
3.5-10.0 
x109/L 
 
Treatments 
DL02 M 1975 1977 2005 20-24 62-73 99-160 5.9-9.8 Phlebotomy 
DL03 F 1982 1987 2005 19-23 58-65 117-145 5.0-7.4 Phlebotomy 
DL04 F 1982 1987 2005 18-20 54-61 101-182 5.0-6.5 Phlebotomy 
DL07 M 1969 1977 2005 19-22 61-66 75-113 4.6-7.6 Phlebotomy 
DL11 M 1971 1977 2005 20-21 68-73 72-96 7.3-7.4 Phlebotomy 
UPN, unique patient number; WBC, white blood cells; RBC, red blood cells; lowest and 
highest values are given 
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Figure 1  Segregation of microsatellite markers on chromosome 3p. Filled black 
symbols represent affected individuals; open symbols, normal individuals; filled grey 
symbols, not studied. Unique patient numbers are placed below the symbols. Haplotypes 
for twelve polymorphic microsatellite markers from D3S1297 to D3S3659 are shown as 
numbers defined arbitrarily according to different sizes of PCR fragments. Two 
haplotypes linked with disease phenotype are boxed. Affected individuals are 
homozygous and carriers are heterozygous for the disease haplotype.  
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The other region on chromosome 18 was 2.8 Mb in size without any obvious candidate 
genes (data not shown). SNP chips array analysis revealed 5 regions in total with the 
highest LOD score of 2.49 throughout the whole genome (Figure 2A). Among them the 
region on chromosome 3 (Figure 2B) and chromosome 18 were consistent with those 
identified by microsatellite mapping. The region on chromosome 3 was reduced to 16 Mb 
whereas the one on chromosome 18 was slightly larger (3.2 Mb) compared to the one 
from microsatellite mapping. Co-segregating regions identified by genome-wide linkage 
microsatelite markers mapping and SNP chip arrays are summarized in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Parametric linkage analysis of 50K SNP array Xba 240 for 13 family 
members. A) The whole genome LOD score curve was plotted on the right side with a 
threshold from –5 to 3, LOD score of 2 is indicated by a red line. Haplotypes of each 
family member are shown on the left side with different colors. For each person the 
maternal allele is on the right and paternal on the left. B) LOD score curve of the 
segregating region on chromosome 3p. The region is consistent with the one from 
microsatellite markers with the highest LOD score 2.49. 
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The top candidate gene VHL was studied intensively. The three exons including 
intron/exon boundaries were sequenced using genomic DNA from one affected family 
member (DL04). The untranslated region (UTR) was sequenced as well using cDNA as a 
template. No mutation was found in the sequence of VHL. Expression of VHL was 
examined by RT-PCR in granulocyte cDNA. Two mRNA splice variants were detectable 
(Figure 3A). Total VHL mRNA levels or the two splice variants determined by real-time 
RT-PCR showed no significant differences between normal and affected family members 
(Figure 3B). VHL protein in platelets was assessed by western blotting (Figure 3C). Both 
protein isoforms translated from the two mRNA variants were detectable in platelets. 
There were no visible variations for the protein sizes or expression levels between the 
unaffected and affect family members.   
 
 
 
 
 
Table 2 Segregating regions identified by Microsatellite linkage mapping and SNP array
analysis.
               Microsatellite Markers                                                    SNP arrays
  Locus             Size (Mb)          Genes                      Locus            Size (Mb)           Genes
     3p                    21                   180                           3p                    16                    139
     18q                  2.8                  22                             18q                  3.2                   29
                                                                              1q                    5.7               57
                                                                              2q                    8.3               49
                                                                              7p                    5.7               51
Total number of genes               202                                                                           325
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Figure 3 Analysis of VHL gene expression. A) VHL expression in platelet cDNA 
detected by RT-PCR. Both isoforms could be detected in all 8 family members. B) 
Expressions of total VHL and two isoforms respectively in platelet cDNA detected by 
real-time PCR. C) Western blotting of VHL protein in platelet proteins  
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Three other candidate genes in segregating regions were chosen for sequencing: 
Chromosome 3 open reading frame 10 (C3orf10) on chromosome 3, v-yes-1 Yamaguchi 
sarcoma viral oncogene homolog 1 (YES-1) and TGFB-induced factor homeobox 1 
(TGIF) on chromosome 18.  However no mutations were found in these three genes. In 
addition to candidate genes in co-segregating regions, we did exon sequencing for genes 
known to be involved in hypoxia sensing and erythropoiesis such as HIF1?, PHD 1, 2 
and 3, EPO, EPO-R and phosphatase and tesin homolog deleted (PTEN) etc.  However 
none of the genes showed polymorphisms linked to the polycythemia in the family. 
Information on all sequenced candidate genes is summarized in Table 3. 
 
 
EPO gene expression levels were determined in BFU-E culture cells in both normoxia 
and hypoxia conditions for 4 affected family members. One unaffected sibling and one 
normal individual were used as controls (Figure 4).  In 3 out of 4 affected family 
members EPO mRNA levels were 4.6 to 7.2 folds higher in hypoxia condition than in 
normoxia culture. The unaffected siblings showed 1.4 fold increase of EPO mRNA in 
Table 3 Overview of analyzed candidate genes
Gene Symbol   Gene Full Name                                               Position                          Main Function
VHL von Hippel-Lindau tumor suppressor    3p26-p25 tumor suppressor; Ubiquitin degradation
C3orf10 chromosome 3 open reading frame 10 3p25.3 uncharacterized hematopoietic stem/progenitor cells
                                                                          protein
YES-1 v-yes-1 Yamaguchi sarcoma viral 18p11.31- tyrosine kinase activity and one of the src
oncogene homolog 1 p11.21 family of proteins
TGIF TGFB-induced factor homeobox 1 18p11.3 transcriptional regulator, mutations associated with
holoprosencephaly type 4
EPO erythropoietin                                         7q22 encoding EPO protein, regulating red cell
differentiation and production
EPO-R erythropoietin-receptor                          19p13.3 encoding EPO receptor, binging with EPO to
activate different cellular pathways
PHD1 prolyl hydroxylase domain containing 1 19q13.2 encodes enzymes responsible for prolyl 
PHD2 prolyl hydroxylase domain containing 2 1q42.1 hydroxylation of HIF-1? and ubiquitin-mediated
PHD3 prolyl hydroxylase domain containing 3 14q13 degradation
HIF-1a hypoxia-inducible factor-1a 14q21-24 an essential transcription factor for maintaining  
oxygen homeostasis
PTEN phosphatase and tesin homolog deleted 10q23.3 a tumor suppressor, negatively regulating
     AKT/PKB signaling pathway
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hypoxia treated BFU-E culture cells. The normal control showed even lower EPO mRNA 
level in hypoxia condition. However one affected family member (DL07) did not show 
significant increase of EPO mRNA levels after hypoxia treatment (1.3 fold).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 EPO gene expression in BFU-E culture cells in normoxia and hypoxia 
condition. Four affected family members, one unaffected sibling and one normal control 
were tested. BFU-E cultures were incubated at normoxia and hypoxia chambers for 14 
days before RNA extraction and real-time PCR. EPO expression levels at normoxia are 
set as 1 to calibrate the expression levels at hypoxia.   
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Discussion 
In this study we analyzed a family with congenital secondary polycythemia with the 
purpose to identify the genetic lesion associated with the phenotype. Genome wide 
mapping by microsatellite markers and SNP chip arrays revealed a total of 5 genetic 
regions linked with the disease, ranging from 2.8 to 21 Mb. The multiple and relatively 
large genetic regions in this family are mainly due to the limited size of the pedigree and 
a high degree of homozygosity in certain genomic regions in some family members. SNP 
arrays are more sensitive than microsatellite marker mapping since the density of SNPs is 
much higher than microsatellite markers. Indeed 3 extra regions were found in SNP 
arrays, whereas two regions (chromosome 3 and chromosome 18) were confirmed by 
both mapping methods. In addition, SNP chip arrays reduced the region on chromosome 
3 by 5 Mb and therefore excluded 41 genes as candidate genes. However the region on 
chromosome 18 was increased by 0.4 Mb with additional 7 genes inside. These 
discrepancies indicate that although SNP arrays with high density of SNP markers 
increase resolusion in genetic linkage analysis, it is not necessarily helping in fine 
mapping because the reduction of the region is totally dependent on recombinations that 
occurred in family members.   
In total, there are 325 genes in the 5 segregating regions. It is feasible to sequence a 
limited number of candidate genes. The most promising candidate gene within the 
segregating regions is VHL, in which a homozygous mutation causes the Chuvash 
polycythemia. We did not find any mutation by sequencing VHL. VHL mRNA and 
protein levels were comparable in affected and unaffected family members. Although the 
family has a similar phenotype and inheritance pattern like Chuvash polycythemia, VHL 
was excluded as the disease-causing gene for this family.  Three other genes in the 
regions were chosen for sequencing and no mutation was found. The criteria for picking 
candidate genes were involvement in hematopoiesis, kinase activity or transcriptional 
regulation. In addtion to candidate genes in co-segregating regions, several key genes 
involved in oxygen sensing and erythropoiesis were also excluded by sequencing. We 
suppose that the undiscovered mutant gene in the segregating regions must have an 
uncharacterized function, which leads to the phenotype in this family.  
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BFU-E cultures in hypoxia showed higher EPO mRNA expression in 3 out of 4 affected 
family members compared to normal controls indicating a hypersensitivity for hypoxia 
condition in patients. There might be a defect in oxygen sensing that contributes to the 
erythrocytosis in this family.  
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PERSPECTIVES 
 
Genetic studies of familial MPD have identified numerous inherited germ-line 
mutations in disease causing genes such as TPO, MPL, EPOR and so on. The 
characterizations of these mutations have helped us to understand not only the 
etiology of the inherited diseases, but also the physiological processes of 
erythropoiesis and thrombopoiesis. In many families, however, the disease 
causing genes remain to be identified to clarify the mechanism underlying the 
inherited phenotypes, which are often similar to the sporadic form of MPD. Some 
of these unknown genetic lesions in families are supposed to facilitate or 
predispose for one or several somatic mutations that cause the sporadic cases of 
MPD. In the first part of my thesis project, I studied HT families by both candidate 
gene approach and genome-wide linkage analysis. Previously reported 
mutations in candidate genes TPO and MPL have been identified in two families 
of our HT collection. One mutation arose de novo, the other from a founder 
effect. TPO and MPL gene have been excluded in 11 HT families and the genetic 
variation causing the thrombocytosis inherited in these families still remains 
unknown. Genome-wide linkage analysis was performed for a large HT pedigree 
containing 20 family members to search for new genetic components.  In a 
second project, a family with congenital secondary polycythemia was analyzed 
by both genome-wide linkage and candidate gene approach. Several genetic 
regions were shown to co-segregate with the disease, but no mutation was 
found.   
 
Mutations causing hereditary thrombocythemia 
TPO and MPL gene mutations 
Five germ-line mutations in the TPO gene and one in the MPL gene have been 
identified in HT families.22,23,25-27,51 The mechanisms causing thrombocytosis are 
different for the TPO and MPL mutations though they both cause the disease via 
the TPO and MPL ligand-receptor mediated pathway. TPO mutations are located 
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in the 5’UTR of the TPO mRNA and increase the efficiency of TPO protein 
translation.21 The MPL mutation is in the transmembrane domain of the receptor 
and results in a hyperactive protein independent of TPO ligation.51 Families with 
TPO germ-line mutations, despite increased translation and excessive production 
of TPO protein, show only slightly elevated or even normal serum TPO levels.22 
A possible explanation is that the increase in platelet and megakaryocyte mass 
activates the feedback regulation system and reaches a new equilibrium at TPO 
levels close to normal.(Liu et al submitted)  Therefore the TPO serum level is not 
necessarily suitable as an indicator for a TPO gene mutation. The clinical 
features of different HT families carrying either TPO or MPL mutation are 
indistinguishable. HT, therefore, is a disease with uniform clinical features but 
heterogeneous molecular genetic causes. 
No mutation in the TPO gene has been found in sporadic ET patients, whereas 
mutations in juxtamembrane domain of MPL have been found in sporadic IMF 
and ET patients.54,55  
Due to the multiple genetic variations for different HT families, combination of 
many small pedigrees for linkage analysis is not feasible since they may have 
different genetic locations for the disease mutations. For many small HT families, 
a candidate gene approach by analyzing TPO and MPL gene is still the best way 
to explore their etiology.  
 
Origins of the mutations 
Recently families carrying the identical TPO or MPL mutations have been 
reported, raising the intriguing question of the origin of these rare germ-line 
mutations in these families (Liu et al. submitted).52 
One splice donor mutation in the TPO gene has been identified both in a Dutch 
family and in a Polish family. Although a very rare event, our data suggest that 
the mutation arose independently in these two families (Liu et al. submitted). 
Recently a mutation in the transmembrane domain of the MPL gene has been 
found in 4 HT families.52 This is the first report of multiple families sharing an 
identical germ-line mutation. In our HT family group of 11 families, one family 
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was found carrying the same MPL mutation. The unexpectedly high frequency of 
this mutation in HT families suggested a founder effect, i.e. all families inherited 
this mutation from a common ancestor. All the six HT families carrying the 
identical MPL mutation were examined by haplotype analysis using 
microsatellites. This analysis revealed that all the families share the same 
genetic characters in the vicinity to the mutation, indicating that the mutant allele 
in these six families may share a common ancestor. It is reasonable to assume 
that more HT families in the general population may carry the same MPL or TPO 
germ-line mutations that either originated de novo or from a founder effect.  
 
Novel genetic components 
In addition to the TPO and MPL gene, unknown disease causing gene(s) remain 
to be identified in some HT families.143,144 Genome-wide linkage study is only 
feasible when the HT pedigree is large enough with a clear inheritance mode and 
relatively high penetrance. These families provide powerful tools to track down 
the genetic variations causing the disease, since the genetic regions co-
segregating with the disease can be located using genome-wide linkage mapping 
methods. By examining genes in the co-segregating region, it is possible to 
identify the novel genetic components involved in the disease.   
 
Genetic regions identified by microsatellites and SNPs 
A large HT family with normal TPO and MPL gene was chosen for genome-wide 
linkage analysis to identify a novel genetic variation causing the thrombocytosis 
in this family. Two different regions on chromosome 9 and 20 displayed co-
segregation with the phenotype. The region on chromosome 9 was confirmed 
using both microsatellite markers and SNP chip arrays, whereas the region on 
chromosome 20 was only detectable in SNP chip arrays. The discrepancies 
might be explained by the much higher density of the SNPs than the 
microsatellite markers, which enables us to discover regions falling between two 
microsatellites or those without informative microsatellite markers located within. 
Similarly, in the linkage analysis for a family with congenital secondary 
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polycythemia, three additional genetic regions have been identified when using 
SNP arrays.  The high density of SNPs increase the power remarkably in 
identifying genetic regions but the power in reducing the size of genetic regions is 
limited since it is mainly determined by the recombinations during meiosis within 
the pedigree. Among all the genetic regions that show linkage to the disease 
phenotype, only one region contains the disease-causing gene. The reasons for 
multiple regions include coincidental segregations and uninformative markers 
within certain regions. The genetic regions confirmed by two methods are more 
reliable and should have priority for further studies.  
  
Functional studies on the candidate gene gelsolin  
All the 29 genes in the region of chromosome 9 have been sequenced to search 
for the novel genetic component causing thrombocytosis in this family. A novel 
polymorphism in the gelsolin gene was found, which changed a glycine into a 
cysteine in the protein sequence. However cell lines transfected with the 
candidate mutant gelsolin did not show any proliferation advantage over the wild 
type. Blood counts were normal in mice transplanted with the candidate mutant 
gelsolin.  These results do not support the hypothesis that gelsolin is the disease-
causing gene in this family, even though the polymorphism in this gene is the 
only variation found so far in the segregating region.  
Further functional studies on gelsolin are planned for the future. The first aim is to 
study the process of platelet releasing in megakaryocytes cultured in vitro. Since 
our data showed that over expression of gelsolin did not increase the proliferation 
rate of cells, the high platelet counts might be due to a defect in the platelet 
releasing process, which remains poorly understood to date. Platelet formation 
and releasing from megakaryocytes requires complicated changes in the 
cytoskeletal organization including microtubule elongation and actin 
assembling.66,176 Actin is the most abundant protein in platelets. Gelsolin, as a 
member of the actin-binding protein family, is thought to function in capping, 
severing, nucleating or bundling actin filaments. Expression of gelsolin protein 
was detected in platelets in our study and many other studies. Knock-out of 
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gelsolin in mice showed abnormal platelet functions.169 Interestingly, abnormal 
platelet aggregation and prolonged bleeding time were also found in affected 
family members studied.166 Therefore it is of interest to see if the candidate 
mutant gelsolin could lead to over-production of platelets or abnormal platelet 
functions. Secondly, bone marrow transplantation using mouse gelsolin 
sequences might be necessary since human and mouse glesolin have 5% 
difference at amino acid sequence. Human gelsolin might not be able to interact 
with mouse signaling molecules in the bone marrow transplantation assay. Due 
to the relatively low efficiency of retrovirus integration in bone marrow 
transplantation (up to 30%), it might be difficult to mimic a germ-line mutation, 
which is present in all cells, to generate a disease phenotype in mice. An 
alternative method for in vivo study could be to generate transgenic mice or 
knock-in micefor the candidate gelsolin mutation.  
 
Sequencing candidate genes 
Although gelsolin is considered as a top candidate gene in this HT family with 
normal TPO and MPL genes, it is possible that another gene might carry the 
disease-causing mutation. Sequencing for genes in the segregating region on 
chromosome 9q has not been fully completed due to some difficulties with some 
PCR. In addition, only 5 candidate genes in the region on chromosome 20q 
identified by SNP chips array were sequenced. There are still 20 genes in this 
area that remain to be sequenced.  
For the family with congenital secondary polycythemia, there are a total of 325 
genes in the 5 segregating regions identified by microsatellite markers and SNP 
arrays. It is only feasible to check a limited number of candidate genes. 
Combination with expression profile data might be helpful for choosing more 
candidate genes for further study.  
 
 
 
 
   
 93
REFERENCES 
 
1. Kondo M WA, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, Shizuru JA, Weissman 
IL. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu 
Rev Immunol. 2003;21:759-806. 
2. Akashi K TD, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that 
gives rise to all myeloid lineages. Nature. 2000;404:193-197. 
3. Kondo M WI, Akashi K. Identification of clonogenic common lymphoid progenitors in 
mouse bone marrow. Cell. 1997;91:661-672. 
4. Kaushansky K DJ. The molecular and cellular biology of thrombopoietin: the primary 
regulator of platelet production. Oncogene. 2002;21:3359-3367. 
5. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-
deficient mice. Science. 1994;265:1445-1447. 
6. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and 
late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996;183:651-656. 
7. Wendling F, Varlet P, Charon M, Tambourin P. MPLV: a retrovirus complex inducing an 
acute myeloproliferative leukemic disorder in adult mice. Virology. 1986;149:242-246. 
8. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative 
truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus 
immortalizes hematopoietic progenitors. Cell. 1990;63:1137-1147. 
9. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the 
human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth 
factor receptor superfamily. Proc Natl Acad Sci USA. 1992;89:5640-5644. 
10. Vigon I, Florindo C, Fichelson S, et al. Characterization of the murine Mpl proto-
oncogene, a member of the hematopoietic cytokine receptor family: molecular cloning, 
chromosomal location and evidence for a function in cell growth. Oncogene. 1993;8:2607-2615. 
11. Skoda RC, Seldin DC, Chiang MK, Peichel CL, Vogt TF, Leder P. Murine c-mpl: a 
member of the hematopoietic growth factor receptor superfamily that transduces a proliferative 
signal. Embo J. 1993;12:2645-2653. 
12. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and 
thrombopoiesis by the c-mpl ligand. Nature. 1994;369:533-538. 
13. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte 
growth and development factor that is a ligand for the cytokine receptor mpl. Cell. 1994;77:1117-
1124. 
14. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin 
cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-568. 
15. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion 
and differentiation by the c-mpl ligand thrombopoietin. Nature. 1994;369:568-571. 
16. Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA 
sequence, expression, and chromosomal localization. Proceedings of the National Academy of 
Sciences of the United States of America. 1994;91:13023-13027. 
17. Chang MS, Mcninch J, Basu R, et al. Cloning and characterization of the human 
megakaryocyte growth and development factor (mgdf) gene. Journal of Biological Chemistry. 
1995;270:511-514. 
18. Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the 
human thrombopoietin gene. Febs Letters. 1994;353:57-61. 
19. Kamura T, Handa H, Hamasaki N, Kitajima S. Characterization of the human 
thrombopoietin gene promoter - A possible role of an Ets transcription factor, E4TF1/GABP. J Biol 
Chem. 1997;272:11361-11368. 
20. Kozak M. Constraints on reinitiation of translation in mammals. Nucleic Acid Res. 
2001;29:5226-5232. 
21. Cazzola M, Skoda RC. Translational pathophysiology: a novel molecular mechanism of 
human disease. Blood. 2000;95:3280-3288. 
   
 94
22. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor 
mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nature Genet. 
1998;18:49-52. 
23. Ghilardi N, Wiestner A, Kikuchi M, Oshaka A, Skoda RC. Hereditary thrombocythemia in 
a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J 
Haematol. 1999;107:310-316. 
24. Ghilardi N, Wiestner A, Skoda RC. Thrombopoietin production is inhibited by a 
translational mechanism. Blood. 1998;92:4023-4030. 
25. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with 
one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood. 1998;92:1091-
1096. 
26. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes 
familial essential thrombocytosis through a mechanism of more efficient translation of TPO mRNA 
[letter]. Blood. 1999;94:1480-1482. 
27. Jorgensen MJ, Raskind WH, Wolff JF, Bachrach HR, Kaushansky K. Familial 
thrombocytosis associated with overproduction of thrombopoietin due to a novel splice donor site 
mutation. Blood. 1998;92, supplement 1:205a (abstract). 
28. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. 
Nucleic Acids Res. 1987;15:8125-8148. 
29. Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:746-754. 
30. Wells JA, de Vos AM. Hematopoietic receptor complexes. Annu Rev Biochem. 
1996;65:609-634. 
31. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-
mediated binding to platelets. Blood. 1996;87:2154-2161. 
32. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and 
degradation of thrombopoietin. Blood. 1997;89:2782-2788. 
33. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-mpl ligand) to 
changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 
1995;85:2720-2730. 
34. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice:  evidence 
against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 
1996;87:567-573. 
35. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin 
mRNA levels are modulated by platelet count. Blood. 1995;86:3668-3675. 
36. Kaser A BG, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, 
Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through 
thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720-2725. 
37. Mignotte V, Vigon I, Decrevecoeur EB, Romeo PH, Lemarchandel V, Chretien S. 
Structure and transcription of the human c-mpl gene (MPL). Genomics. 1994;20:5-12. 
38. Li J SD, Kuter DJ. Cloning and functional characterization of a novel c-mpl variant 
expressed in human CD34 cells and platelets. Cytokine. 2000;12:835-844. 
39. Coers J, Ranft C, Skoda RC. A Truncated Isoform of c-Mpl with an Essential C-terminal 
Peptide Targets the Full-length Receptor for Degradation. J Biol Chem. 2004;279:36397-36404. 
40. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in 
human myeloproliferative disorders. Lancet. 2005;365:1054-1061. 
41. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to 
constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148. 
42. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in 
myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. 
43. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia 
vera. J Biol Chem. 2005;280:22788-22792. 
44. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in 
polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. 
Cancer Cell. 2005;7:387-397. 
   
 95
45. Scott LM TW, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, 
McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. JAK2 exon 12 
mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468. 
46. Saharinen P TK, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its 
pseudokinase domain. Mol Cell Biol. 2000;20:3387-3395. 
47. Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital 
amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A. 1999;96:3132-3136. 
48. van den Oudenrijn S BM, Folman CC, Peters M, Faulkner LB, de Haas M, von dem 
Borne AE. Mutations in the thrombopoietin receptor, Mpl, in children with congenital 
amegakaryocytic thrombocytopenia. Br J Haematol. 2000;110:441-448. 
49. Ballmaier M GM, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, 
Strauss G, Welte K. c-mpl mutations are the cause of congenital amegakaryocytic 
thrombocytopenia. Blood. 2001;97:139-146. 
50. Ballmaier M GM, Krukemeier S, Welte K. Thrombopoietin is essential for the 
maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients 
with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci. 2003;996:17-25. 
51. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a 
dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for 
thrombopoietin. Blood. 2004. 
52. Teofili L GF, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, 
Larocca LM. Markers of myeloproliferative diseases in childhood polycythemia vera and essential 
thrombocythemia. J Clin Oncol. 2007;25:1048-1053. 
53. Onishi M, Mui ALF, Morikawa Y, et al. Identification of an oncogenic form of the 
thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Blood. 1996;88:1399-
1406. 
54. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and 
other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476. 
55. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in 
myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270. 
56. Zauli G CL. Human megakaryocyte biology and pathophysiology. Crit Rev Oncol 
Hematol. 1995;21:135-157. 
57. Kuter DJ GD, Rosenberg RD. Transforming growth factor beta inhibits megakaryocyte 
growth and endomitosis. Blood. 1992;79:619-626. 
58. Gandhi MJ DJ, Reems JA, Thorning D, Lannutti BJ. A novel strategy for generating 
platelet-like fragments from megakaryocytic cell lines and human progenitor cells. Blood Cells 
Mol Dis. 2005;35:70-73. 
59. Lannutti BJ BN, Gandhi MJ, Reems JA, Drachman JG. Induction of polyploidization in 
leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656. Blood. 
2005;105:3875-3878. 
60. Crispino J. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 
2005;16:137-147. 
61. Shivdasani RA FY, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the 
critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. 
Embo J. 1997;16:3965-3973. 
62. Nichols KE CJ, Poncz M, White JG, Orkin SH, Maris JM, Weiss MJ. Familial 
dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat 
Genet. 2000;24:266-270. 
63. Muntean AG CJ. Differential requirements for the activation domain and FOG-interaction 
surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005;106:1223-
1231. 
64. Elagib KE RF, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 
coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333-4341. 
65. Heller PG GA, Gandhi MJ, Cummings CL, Pirola CJ, Marta RF, Kornblihtt LI, Drachman 
JG, Molinas FC. Low Mpl receptor expression in a pedigree with familial platelet disorder with 
predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood. 
2005;105:4664-4670. 
   
 96
66. Lecine P IJ, Kim SW, Villeval JL, Shivdasani RA. Hematopoietic-specific beta 1 tubulin 
participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2. 
Blood. 2000;96:1366-1373. 
67. Deveaux S C-KS, Shivdasani RA, Andrews NC, Filipe A, Kuzniak I, Orkin SH, Roméo 
PH, Mignotte V. p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes. 
Embo J;16:5654-5661. 
68. Tiwari S IJ, Barral DC, Mules EH, Novak EK, Swank RT, Seabra MC, Shivdasani RA. A 
role for Rab27b in NF-E2-dependent pathways of platelet formation. Blood. 2003;102:3970-3979. 
69. Schulze H KM, Bergmeier W, Italiano JE, Wahl SM, Shivdasani RA. Interactions between 
the megakaryocyte/platelet-specific beta1 tubulin and the secretory leukocyte protease inhibitor 
SLPI suggest a role for regulated proteolysis in platelet functions. Blood. 2004. 
70. Lecine P, Villeval JL, Vyas P, Swencki B, Xu Y, Shivdasani RA. Mice lacking transcription 
factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a 
platelet production defect that is intrinsic to megakaryocytes. Blood. 1998;92:1608-1616. 
71. Onodera K SJ, Motohashi H, Yamamoto M, Engel JD. Perinatal synthetic lethality and 
hematopoietic defects in compound mafG:mafK mutant mice. Embo J. 2000;19:1335-1345. 
72. Ravid K LJ, Zimmet JM, Jones MR. Roads to polyploidy: the megakaryocyte example. J 
Cell Physiol. 2002;190:7-20. 
73. Nagata Y, Muro Y, Todokoro K. Thrombopoietin-induced polyploidization of bone marrow 
megakaryocytes is due to a unique regulatory mechanism in late mitosis. J Cell Biol. 
1997;139:449-457. 
74. Vitrat N, Cohen-Solal K, Pique C, et al. Endomitosis of human megakaryocytes are due 
to abortive mitosis. Blood. 1998;91:3711-3723. 
75. Wright J. The origin and nature of blood platelets. Boston Med Surg J. 1906;154:643-645. 
76. Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb 
Haemost. 2003;1:1587-1592. 
77. Choi ES NJ, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from 
proplatelet-displaying human megakaryocytes are functional. Blood. 1995;85:402-413. 
78. Cramer EM NF, Guichard J, Breton-Gorius J, Vainchenker W, Massé JM, Debili N. 
Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood. 
1997;89:2336-2346. 
79. Italiano JE, Jr., Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled 
principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell 
Biol. 1999;147:1299-1312. 
80. Schwer HD LP, Tiwari S, Italiano JE, Hartwig JH, Shivdasani RA. A lineage-restricted 
and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood 
platelets. Curr Biol. 2001;11:579-586. 
81. Freson K DVR, Wittevrongel C, Thys C, Defoor J, Vanhees L, Vermylen J, Peerlinck K, 
Van Geet C. The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular 
disease in men by modulating platelet function and structure. Blood. 2005;106:2356-2362. 
82. Balduini CL IA, Savoia A. Inherited thrombocytopenias: from genes to therapy. 
Haematologica. 2002;87:860-880. 
83. Hamilton RW SB, Ottie JN, Storch AE, Saleem A, White JG. Platelet function, 
ultrastructure, and survival in the May-Hegglin anomaly. Am J Clin Pathol. 1980;74:665-668. 
84. Canobbio I NP, Pecci A, Balduini A, Balduini CL, Torti M. Altered cytoskeleton 
organization in platelets from patients with MYH9-related disease. J Thromb Haemost. 
2005;3:1026-1035. 
85. Léon C EA, Hechler B, Aleil B, Freund M, Ravanat C, Jourdain M, Nonne C, Weber J, 
Tiedt R, Gratacap MP, Severin S, Cazenave JP, Lanza F, Skoda R, Gachet C. Megakaryocyte-
restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation 
and secretion. Blood. 2007;110:3183-3191. 
86. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-
E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67. 
87. Bonsdorff EJ, E. A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand. 
1948;16:150-170. 
   
 97
88. Goldwasser E. Erythropoietin: a somewhat personal history. Perspect Biol Med. 
1996;40:18-32. 
89. Miyake T KC, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 
1977;252:5558-5564. 
90. Jacobs K SC, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, 
Hewick R, Fritsch EF, et al. Isolation and characterization of genomic and cDNA clones of human 
erythropoietin. Nature. 1985;313:806-810. 
91. Lin FK SS, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, 
Stabinsky Z, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci 
U S A. 1985;82:7580-7584. 
92. Powell JS BK, Lebo RV, Adamson JW. Human erythropoietin gene: high level expression 
in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci U S A. 
1986;83:6465-6469. 
93. Watkins PC ER, Hoffman N, Stanislovitis P, Beck AK, Galli J, Vellucci V, Gusella JF, 
Shows TB. Regional assignment of the erythropoietin gene to human chromosome region 7pter---
-q22. Cytogenet Cell Genet. 1986;42:214-218. 
94. Law ML CG, Lin FK, Wei Q, Huang SZ, Hartz JH, Morse H, Lin CH, Jones C, Kao FT. 
Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc 
Natl Acad Sci U S A. 1986;83:6920-6924. 
95. Recny MA SH, Kim Y. Structural characterization of natural human urinary and 
recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol 
Chem. 1987;262:17156-17163. 
96. Blanchard KL AA, Galson DL, Bunn HF. Hypoxic induction of the human erythropoietin 
gene: cooperation between the promoter and enhancer, each of which contains steroid receptor 
response elements. Mol Cell Biol. 1992;12:5373-5385. 
97. Lee-Huang S LJ, Kung HF, Huang PL, Lee L, Huang PL. The human erythropoietin-
encoding gene contains a CAAT box, TATA boxes and other transcriptional regulatory elements 
in its 5' flanking region. Gene. 1993;128:227-236. 
98. Dame C SM, Lim KC, Leach KM, Fandrey J, Ma Y, Knöpfle G, Engel JD, Bungert J. 
Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem. 2004;279:2995-2961. 
99. Imagawa S YM, Miura Y. Negative regulation of the erythropoietin gene expression by 
the GATA transcription factors. Blood. 1997;89:1430-1439. 
100. La Ferla K RC, Jelkmann W, Hellwig-Bürgel T. Inhibition of erythropoietin gene 
expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J. 
2002;16:1811-1813. 
101. Nakano Y IS, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, 
Takahashi S, Nagasawa T, Yamamoto M. Oral administration of K-11706 inhibits GATA binding 
activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo 
mouse model of anemia of chronic disease. Blood. 2004;104:4300-4307. 
102. White JR HR, Lee SR, Craigon MH, Binley K, Price T, Beard GL, Mundy CR, Naylor S. 
Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying 
regulators of angiogenesis. Genomics. 2004;83:1-8. 
103. Manalo DJ RA, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. 
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 
2005;105:659-669. 
104. Allen JW KS, Johnson RS, Bhatia SN. In vitro liver tissue model established from 
transgenic mice: role of HIF-1alpha on hypoxic gene expression. Tissue Eng. 2006;12:3135-
3147. 
105. Chang SC SD, Goldwasser E. Evidence for an erythropoietin receptor protein on rat bone 
marrow cells. Biochem Biophys Res Commun. 1974;57:399-405. 
106. Krantz SB GE. Specific binding of erythropoietin to spleen cells infected with the anemia 
strain of Friend virus. Proc Natl Acad Sci U S A. 1984;81:7574-7578. 
107. D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. Journal of 
Clinical Investigation. 1990;86:681-687. 
108. Youssoufian H LG, Neumann D, Yoshimura A, Lodish HF. Structure, function, and 
activation of the erythropoietin receptor. Blood. 1993;81:2223-2236. 
   
 98
109. Cheetham JC SD, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS. 
NMR structure of human erythropoietin and a comparison with its receptor bound conformation. 
Nat Struct Biol. 1998;5:861-866. 
110. Livnah O SE, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic 
evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 
1999;283:987-990. 
111. Remy I WI, Michnick SW. Erythropoietin receptor activation by a ligand-induced 
conformation change. Science. 1999;283:990-993. 
112. Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital 
polycythemia. Am J Hematol. 2001;68:115-121. 
113. Erslev AJ CJ, Besarab A. Why the kidney? Nephron. 1985;41:213-216. 
114. Semenza GL, GL W. A nuclear factor induced by hypoxia via de novo protein synthesis 
binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. 
Mol Cell Biol. 1992;12:5447-5454. 
115. Semenza GL NM, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an 
enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci U S A. 
1991;88:5680-5684. 
116. Salceda S CJ. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded 
by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia 
depends on redox-induced changes. J Biol Chem. 1997;272:22642-22647. 
117. Huang LE GJ, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is 
mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc 
Natl Acad Sci U S A. 1998;95:7987-7992. 
118. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau 
ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-472. 
119. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by 
proline hydroxylation: implications for O2 sensing. Science. 2001;292:464-468. 
120. Epstein AC GJ, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, 
Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, 
Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs 
define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43-54. 
121. Bruick RK MS. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 
2001;294:1337-1340. 
122. Yu F WS, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive 
proline hydroxylation. Proc Natl Acad Sci U S A. 2001;98:9630-9635. 
123. Pugh CW ORJ, Nagao M, Gleadle JM, Ratcliffe PJ. Activation of hypoxia-inducible factor-
1; definition of regulatory domains within the alpha subunit. J Biol Chem. 1997;272:11205-11214. 
124. Maxwell PH WM, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh 
CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible 
factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275. 
125. Ohh M PC, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. 
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von 
Hippel-Lindau protein. Nat Cell Biol. 2000;2:423-427. 
126. Mahon PC HK, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and 
VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15:2675-2686. 
127. McNeill LA HK, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. Hypoxia-inducible 
factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-
803. Biochem J. 2002;367:571-575. 
128. Lando D PD, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF 
transactivation domain a hypoxic switch. Science. 2002;295:858-861. 
129. Tian H MS, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription 
factor selectively expressed in endothelial cells. Genes Dev. 1997;11:72-82. 
130. Ema M TS, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS 
factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF 
expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S 
A. 1997;94:4273-4278. 
   
 99
131. Flamme I FT, von Reutern M, Kappel A, Damert A, Risau W. HRF, a putative basic helix-
loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha 
and developmentally expressed in blood vessels. Mech Dev. 1997;63:51-60. 
132. Luo G GY, Jain S, Chan WK, Carr KM, Hogenesch JB, Bradfield CA. Molecular 
characterization of the murine Hif-1 alpha locus. Gene Expr. 1997;6:287-299. 
133. Wiesener MS JJ, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, 
Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU. 
Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different 
organs. FASEB J. 2003;17:271-273. 
134. Rosenberger C HS, Rosen S, Shina A, Goldfarb M, Griethe W, Frei U, Reinke P, 
Bachmann S, Eckardt KU. Up-regulation of HIF in experimental acute renal failure: evidence for a 
protective transcriptional response to hypoxia. Kidney Int. 2005;67:531-542. 
135. Warnecke C ZZ, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU. Differentiating 
the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use 
of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB 
J. 2004;18:1462-1464. 
136. Hara S HJ, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-
inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by 
HIF-3alpha. Biochem Biophys Res Commun. 2001;287:808-813. 
137. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital 
Chuvash polycythemia. Nat Genet. 2002;32:614-621. 
138. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl 
hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A. 2006;103:645-
649. 
139. Skoda R PJ. Lessons from familial myeloproliferative disorders. Semin Hematol. 
2005;42:266-273. 
140. Harrison CN, Gale RE, Wiestner AC, Skoda RC, Linch DC. The activating splice mutation 
in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential 
thrombocythaemia. Br J Haematol. 1998;102:1341-1343. 
141. Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Molecular analysis of the 
erythropoietin receptor system in patients with polycythaemia vera. British Journal of 
Haematology. 1994;88:794-802. 
142. Le Couedic JP, Mitjavila MT, Villeval JL, et al. Missense mutation of the erythropoietin 
receptor is a rare event in human erythroid malignancies. Blood. 1996;87:1502-1511. 
143. Kunishima S, Mizuno S, Naoe T, Saito H, Kamiya T. Genes for thrombopoietin and c-mpl 
are not responsible for familial thrombocythaemia: a case study. Br J Haematol. 1998;100:383-
386. 
144. Wiestner A, Padosch SA, Ghilardi N, et al. Hereditary thrombocythaemia is a genetically 
heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary 
thrombocythaemia. Br J Haematol. 2000;110:104-109. 
145. Kralovics R, Sokol L, Broxson EH, Jr., Prchal JT. The erythropoietin receptor gene is not 
linked with the polycythemia phenotype in a family with autosomal dominant primary 
polycythemia. Proceedings of the Association of American Physicians. 1997;109:580-585. 
146. Collins A FJ, Teague J, Morton NE. A metric map of humans: 23,500 loci in 850 bands. 
Proc Natl Acad Sci U S A. 1996;93:14771-14775. 
147. Broman KW MJ, Sheffield VC, White RL, Weber JL. Comprehensive human genetic 
maps: individual and sex-specific variation in recombination. Am J Hum Genet. 1998;63:861-869. 
148. Clayton DG WN, Smyth DJ, Pask R, Cooper JD, Maier LM, Smink LJ, Lam AC, Ovington 
NR, Stevens HE, Nutland S, Howson JM, Faham M, Moorhead M, Jones HB, Falkowski M, 
Hardenbol P, Willis TD, Todd JA. Population structure, differential bias and genomic control in a 
large-scale, case-control association study. Nat Genet. 2005;37:1243-1246. 
149. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative 
disorders: complications, survival and causes of death. Ann Hematol. 2000;79:312-318. 
150. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol. 
2001;38:21-24. 
   
 100
151. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential 
thrombocythemia. Seminars in Hematology. 1999;36:9-13. 
152. Jaffe ES, Harris NL, Stein H. World Health Organization Classification of Tumours.  
Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 
Press; 2001. 
153. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) 
classification of the myeloid neoplasms. Blood. 2002;100:2292-2302. 
154. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative 
disorders--current diagnostic approach. Semin Hematol. 2005;42:184-195. 
155. Kovacsovics TJ, Bachelot C, Toker A, et al. Phosphoinositide 3-kinase inhibition spares 
actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem. 
1995;270:11358-11366. 
156. Bauermeister DE. Quantitation of bone marrow reticulin--a normal range. Am J Clin 
Pathol. 1971;56:24-31. 
157. Rudzki Z, Kawa R, Oko? K, Szczygie? E, Stachura J. Objective, planimetry-based 
assessment of megakaryocyte histological pictures in Philadelphia chromosome-negative chronic 
myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool. Virchows Archiv. 
2005;12:1-9. 
158. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of 
patients with chronic myeloproliferative disorders. Blood. 2003;102:1869-1871. 
159. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. 
160. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative 
disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 
2005;106:3374-3376. 
161. Weber JL, Wong C. Mutation of human short tandem repeats. Hum Mol Genet. 
1993;2:1123-1128. 
162. Li W. Molecular evolution. Sunderland, MA: Sinauer; 1997. 
163. Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow 
biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification. Ann 
Hematol. 1999;78:495-506. 
164. Bartl R, Frisch B. Clinical significance of bone marrow biopsy and plasma cell 
morphology in MM and MGUS. Pathol Biol (Paris). 1999;47:158-168. 
165. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in 
plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106:345-
356. 
166. Eyster ME, Saletan SL, Rabellino EM, et al. Familial essential thrombocythemia. Am J  
Med. 1986;80:497-502. 
167. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, C. L. dChipSNP: significance curve 
and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004;20:1233-
1240. 
168. Towbin H, Staehelin T, J G. Electrophoretic transfer of proteins from polyacrylamide gels 
to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 
1979;76:4350-4354. 
169. Witke W SA, Hartwig JH, Azuma T, Stossel TP, Kwiatkowski DJ. Hemostatic, 
inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell. 1995;81:41-51. 
170. Maury CP BM. Isolation and characterization of cardiac amyloid in familial amyloid 
polyneuropathy type IV (Finnish): relation of the amyloid protein to variant gelsolin. biochem 
Biophys Acta. 1990;1096:84-86. 
171. Ghiso J HM, Prelli F, Novello J, Frangione B. Gelsolin variant (Asn-187) in familial 
amyloidosis, Finnish type. Biochem J. 1990;272:827-830. 
172. de la Chapelle A TR, Boysen G, Santavy J, Bleeker-Wagemakers L, Maury CP, Kere J. 
Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic 
acid at residue 187. Nat Genet. 1992;2:157-160. 
173. Geng YJ AT, Tang JX, Hartwig JH, Muszynski M, Wu Q, Libby P, Kwiatkowski DJ. 
Caspase-3-induced gelsolin fragmentation contributes to actin cytoskeletal collapse, nucleolysis, 
   
 101
and apoptosis of vascular smooth muscle cells exposed to proinflammatory cytokines. Eur J Cell 
Biol. 1998;77:294-302. 
174. Sagawa N FH, Banno Y, Nozawa Y, Katoh H, Kuzumaki N. Gelsolin suppresses 
tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10. Br J 
Cancer. 2003;88:606-612. 
175. De Corte V BE, Boucherie C, Mareel M, Vandekerckhove J, Gettemans J. Gelsolin-
induced epithelial cell invasion is dependent on Ras-Rac signaling. Embo J. 2002;21:6781-6790. 
176. Rojnuckarin P KK. Actin reorganization and proplatelet formation in murine 
megakaryocytes: the role of protein kinase calpha. Blood. 2001;97:154-161. 
177. Prchal JT. Molecular biology of polycythemias 
Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Intern 
Med. 2001;40:681-687. 
178. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the 
VHL gene. Blood Cells, Molecules & Diseases. 2002;28:57-62. 
179. GL S. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. 
Pediatr Res. 2001. 
180. Wang GL, Jiang BH, GL. S. Effect of protein kinase and phosphatase inhibitors on 
expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun. 1995;216:669-675. 
181. Sutter CH, Laughner E, GL. S. Hypoxia-inducible factor 1alpha protein expression is 
controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense 
mutations. Proc Natl Acad Sci U S A. 2000;97:4748-4753. 
182. Livak KJ, TD S. Analysis of relative gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 102
 
CURRICULUM VITAE 
 
Family Name:  LIU       
First Name:  Kun     
Date of Birth:   May 3rd, 1976 
Nationality:  China     
Marriage status: Single                 
Mailing Address: Ryffstrasse 58, Basel 4056, Switzerland 
Telephone:  061 265 3282 (Office); 0764455592 (Mobile) 
Email:    kun.liu@unibas.ch  
 
Education 
 
PhD (Biomedical Research)   University of Basel, Switzerland          2007 
Master of Science    National University of Singapore   2003 
Bachelor of Medicine (M.B.B.S) China Medical University    2001 
 
 
Research Experience 
 
10/2003 — present PhD student 
Experimental Hematology laboratory, Department of Research, University Hospital Basel 
 
Thesis: Genetic studies of hereditary myeloproliferative diseases 
 
07/2001 — 10/2003 Research Scholar (Master sponsored by research scholarship) 
Hepato-Oncogenetics Lab, Department of Physiology, Faculty of Medicine, National 
University of Singapore 
 
Thesis: Exploration of the functional significance of mig-2 in human cancer cell 
susceptibility to cytotoxic agents 
 
 
Professional Skills 
 
General Research skills  
- Manage and develop research projects independently during graduate studies 
- Write manuscripts; Contribute to research grant proposal writing 
- Give public presentations; Instruct new student in lab 
 
Molecular & Cell Biology 
- PCR; real-time PCR; Molecular Cloning; Western blotting 
- Cell culture; retrovirus productionand infection of cell lines and primary cells; Cell 
proliferation assays (XTT/MTT) 
- FACS analysis; Apoptosis assay (TUNEL) 
 
Genetics 
- Affymetrix SNP chip arrays; dCHIP analysis 
   
 103
- DNA sequencing; Mutation screening 
- Microsatellite mapping; Fragment analysis 
 
Animal experiments 
- Holding animal working permit in Switzerland  
- Experience in mouse blood sampling, organ removal/dissection, and bone marrow 
transplantation 
 
Hematology 
- Blood cell separation; EEC culture; transformation of B lymphocytes from patients with 
EBV 
 
 
Other Experience 
 
01/2000 — 07/2001 Medical Intern        
The 2nd Affiliated Hospital of China Medical University, Shenyang, China 
Tasks: Practice clinical medicine in Department of Internal Medicine, Surgical 
Department, Department of Gynaecology and Obstetrics, and Department of Paediatrics 
 
09/1995 — 01/2000 Part-time Tutor 
Tasks:Instructing high school students in English, Chinese and Mathematics 
 
  
Extra-curricular activities 
 
Chairman       Association of Chinese Students and Scholars in Basel    (2006-2007) 
Vice Chairman      Association of Chinese Students and Scholars in Basel    (2004-2006) 
Representative     Student Union of China Medical University                         (1995-2001)  
 
 
 
Scholarship & Awards 
 
Research scholarship by National University of Singapore    (2001—2003) 
Yearly Prize University Scholarship by China Medical University   (1995--- 2000) 
Third Class Prize in China National College Students English Contest   (1999) 
Excellent Student Leader by China Medical University     (1997) 
 
 
Publications 
 
• A de novo splice donor mutation in the thrombopoietin gene causes hereditary 
thrombocythemia in a Polish family (in revision) 
 
• Mutation analysis in families with hereditary thrombocythemia and identification of a 
founder effect for a MPL mutation (in press) 
 
• Genetic association analysis of a family with congenital secondary polycythemia 
(manuscript in preparation) 
